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“Life has many ways of testing a person’s will, either by having nothing happen at all or 
by having everything happen all at once.” 
― Paulo Coelho, The Alchemist 
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ABSTRACT 
 
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and 
the second leading cause of cancer mortality. Despite the prevalence of HCC, there is only 
one FDA approved drug for the advanced disease, which extends lifespan by only 2-3 
months and is associated with multiple side effects. Late SV40 Factor (LSF) has been 
shown to function as an oncogenic transcription factor in HCC, making it a promising 
protein target for HCC therapy. A library of dihydroquinolinones, termed FQIs, have been 
shown to inhibit LSF-DNA binding in in vitro and cellular assays. The lead compound 
FQI-1 causes dramatic mitotic defects in HCC cell lines, but has no or only limited growth 
effects on immortalized human hepatocytes or primary mouse hepatocytes. Additionally, 
FQI-1 has proven efficacious in in vivo HCC mouse models, with no evidence of associated 
toxicity. 
The dihydroquinolinones are promising compounds for a molecularly targeted 
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therapy against HCC. Herein, the library of compounds was expanded and tested for 
potency in an aggressive HCC cell line, as well as for transactivation activity against the 
LSF and closely related family of transcription factors. Direct target engagement is shown 
for the first time with cellular thermal stability assays in HCC cell lysates. The lead 
compound is further shown to have a promising pharmacokinetic and tolerability profile in 
rats, supporting the development as a drug candidate. As a potential driver of mitosis, LSF 
may have a broader role in cancers beyond HCC. High-throughput screening identified 
hematopoietic cancer lineages as particularly sensitive to the dihydroquinolinones. As a 
proof-of-concept, the hematopoietic cell line U937 is shown to express high levels of LSF 
protein, and undergoes extensive apoptosis when treated with dihydroquinolinones or 
siRNA against the LSF subfamily.   
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CHAPTER ONE 
 
Molecular targeting of the oncogenic transcription factor LSF in 
Hepatocellular Carcinoma 
 
1.1 INTRODUCTION 
Primary liver cancer is the sixth leading cause of cancer worldwide and the second 
leading cause of cancer related mortality. There is an unmet clinical need for an effective 
hepatocarcinogenesis chemotherapeutic with limited associated toxicity. Molecular 
targeted cancer therapies involve drugs designed to interfere with specific molecules 
necessary for tumor growth and progression, ideally while leaving normal tissue 
unperturbed. The transcription factor Late SV40 Factor (LSF) has been shown to be an 
oncogene in the predominant form of primary liver cancer, Hepatocellular carcinoma 
(HCC). A library of small molecule dihydroquinolinone inhibitors - termed Factor 
Quinolinone Inhibitors (FQIs) - inhibit LSF transcriptional activity in vitro. The lead 
compound FQI-1 decreases cell proliferation and causes aberrant mitosis in HCC cells, 
with no or limited effect, respectively, on primary or immortalized hepatocytes. In vivo 
mouse disease models show FQI-1 treatment results in a robust decrease in HCC 
tumorigenicity with no apparent toxicity. 
Herein, the dihydroquinolinone library is expanded to improve antiproliferative and 
anti-transcriptional activity, compound solubility, pharmacokinetics, and in life 
tolerability. It is demonstrated for the first time that the dihydroquinolinones directly 
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engage LSF, and LSF paralogous proteins, in lysates of Hepatocellular carcinoma cells. 
 
1.2 BACKGROUND 
1.2.1 Hepatocellular Carcinoma (HCC): An unmet clinical need 
Primary liver cancer is the sixth most common cause of cancer worldwide, and the 
second leading cause of cancer mortality with more than 600,000 deaths reported 
internationally each year1,2. Liver cancer has several subtypes and the dominant subtype 
Hepatocellular Carcinoma (HCC) accounts for about 85% of all cases in most countries1. 
Globally, HCC disproportionally impacts men with rates twice as high as women (Figure 
1.1)3. More than 80% of HCC cases are developed from cirrhosis. Cirrhosis results from a 
number of underlying conditions including hepatitis B (HBV), hepatitis C (HCV), 
aflatoxins, fatty liver disease, nonalcoholic steatohepatitis (NASH), diabetes, obesity, and 
alcohol and tobacco use1,2. The incidence of HCC is a global health problem, however it is 
not evenly distributed throughout the world (Figure 1.1). The highest rates of HCC occur 
in Africa and east Asia4, both areas with endemic HBV infection1,5. Hepatitis B is the 
leading risk factor for HCC globally and accounts for at least 50% of cases5. The leading 
risk factors for HCC in the United States include both HBV and/or HCV, heavy alcohol 
consumption, obesity, diabetes, and tobacco smoking6. Incidence of HCC in the United 
States has more than tripled since 19806 with an average 3% increase in incidence each 
year over the last ten years7. With an overall 5-year survival rate of only 17.5%7, the 
increasing incidence rate of HCC will continue to be a major global health problem for the 
foreseeable future. 
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Figure 1.1 Gender specific and age-standardized HCC incidence and mortality rate (per 100,000) by 
region and development status in 2012. Image taken from Ref 4. 
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The prognosis and treatment of HCC is guided by the tumor stage burden in 
addition to overall liver heath. Management of HCC has been standardized according to 
clinical staging systems aiming to accurately classify HCC patients with different 
therapeutic options.8 The Barcelona-Clinic Liver Cancer (BCLC) classification has 
emerged as the leading staging and treatment strategy8,9. Tumor stage is stratified with 
assessment of liver function (per Child–Pugh class) and consideration of the patient’s 
physical status and cancer related symptoms (per ECOG performance status)10,11. The 
Barcelona Clinic Liver Cancer group first proposed the model in 1999, structured from 
results on the analysis of several cohort and randomized controlled studies10,11. The notable 
feature of the BCLC system is the assignment of treatment recommendations for each stage 
based on the best treatment options available. The system is updated as new investigational 
results emerge. The American Association for the Study of Liver Disease, American 
Gastroenterology Association, European Association for the Study of Liver, and the 
European Organization for the Research and Treatment of Cancer currently endorse BCLC 
as the standard system for HCC management8.  
The BCLC staging system (Figure 1.2) divides patients into five prognostic 
categories each with a distinct treatment option. The very early (BCLC 0) and early stage 
(BCLC A) patients have preserved liver function with limited disease confined to the liver. 
Early stage patients are candidates for hepatic resection, orthotopic liver transplantation 
and percutaneous local ablation. These potentially curative treatments provide a five-year 
survival rate of 75% in well selected patients.10,11 Intermediate stage patients (BCLC B) 
have a larger tumor burden preventing the above treatment options, however liver function 
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is preserved (Child–Pugh A-B) and patients are cancer-asymptomatic. Transarterial 
chemoembolization (TACE), a palliative treatment with clinical benefits ranging from 16 
to 22 months, is the standard of care (SOC) for these patients.12 Hepatocarcinogenesis is a 
rapid process marked by early vascularization and most patients are diagnosed at advanced 
stage (BCLC C) due to limitations in screening technology. Advanced stage patients have 
progressed beyond BCLC B, exhibit extrahepatic spread, vascular invasion  and/or cancer 
related symptoms (ECOG grade 1-2).11 The multi-kinase inhibitor Sorafenib is the only 
effective systemic treatment for these patients. Sorafenib improves median survival time 
by about 3 months13. Patients with terminal-stage disease (BCLC D) have tumors of any 
size with severe impairment of liver function (Child–Pugh C) and have advanced cancer 
symptoms (ECOG grade >2). There is no specific treatment in these cases, and patients 
have an average predicted survival of 3 months.10,11  
 
Figure 1.2 Barcelona-Clinic Liver Cancer (BCLC) staging classification and treatment schedule 
Staging is linked to treatment indication according to evidence-based data, as put forth in Ref 10 and Ref 12. 
See text for details. 
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1.2.2 Clinical benefit of Sorafenib in advanced HCC 
Sorafenib (Nexavar®) is an orally bioavailable small molecule that is the only 
approved systemic therapy for advanced stage HCC, as it is the only drug demonstrated to 
provide a survival benefit over supportive care. Sorafenib acts as a dual-inhibitor, 
inhibiting cell proliferation by targeting the RAF/MEK/ERK pathway in tumor cells while 
concomitantly exerting antiangiogenic effects by targeting receptor tyrosine kinases 
VEGFR/PDGFR and their associated signaling cascades required for tumor vasculature.14 
Sorafenib was approved in the United States for advanced HCC based on the Sorafenib 
Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial13. The 
SHARP trial was a multicenter phase III, randomized, double-blind, placebo-controlled 
trial of 602 advanced HCC patients (>95% Child-Pugh A). Sorafenib treated patients had 
a near 3-month median survival benefit as compared with those who received placebo. No 
symptom palliation was seen in the Sorafenib treatment group. The time to symptomatic 
progression did not differ significantly between the two groups and adverse effects such as 
diarrhea, weight loss, hand–foot skin reaction, alopecia, anorexia, and voice changes 
occurred at a higher frequency in the Sorafenib group than in the placebo group.13 The 
results of the SHARP trial were validated in the Asia-Pacific trial, a second phase III 
randomized, placebo-controlled trial in patients predominantly with HBV infection-related 
advanced stage HCC15.  
The American Society of Clinical Oncology (ASCO) has proposed a ‘Value 
Framework’ algorithm aiming to assess the value of cancer treatments based on clinical 
benefit, side effects, and improvement of symptoms or quality of life in the context of 
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cost16. Applying this framework to the SHARP trial, Sorafenib scores an overall Net Health 
Benefit (NHB) of 24.4 (Figure 1.3; calculations Appendix 1). The NHB is a weighted 
measure of a treatment’s benefits and side effects, and represents any additional benefit a 
treatment may have16. A low NHB indicates there is little added benefit to the treatment 
whereas a high score indicates there is significant additional benefit and/or lower toxicity. 
A score of zero indicates no difference between treatment groups. The average monthly 
cost of Sorafenib in the United States is approximately $10,00017. The high cost, modest 
increase in survival, and low calculated NHB of 24.4, suggest inadequate clinical benefit 
with Sorafenib treatment. In fact, the National Institute for Health and Care Excellence in 
the UK does not recommend Sorafenib for advanced stage HCC patients because of the 
associated toxicity and modest survival benefit18. All trials with new agents inhibiting 
Figure 1.3 ASCO Value Framework for Sorafenib  
Clinical benefit, toxicity, net health benefit (NHB), and cost of Sorafenib using the American Society of 
Clinical Oncology Value Framework. The data for each parameter are shown above the bar. Clinical 
outcomes are taken from the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol trial. 
Drug Acquisition Cost (DAC) is based on cost per month. Data based on SHARP trial (Ref 13).  
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either the same pathways as Sorafenib or different pathways involved in liver 
carcinogenesis and angiogenesis have failed to demonstrate survival benefits19. There is an 
unmet clinical need for the development of new strategies to treat advanced HCC patients 
with limited toxicity. 
 
1.2.3 Oncogene addiction as a rationale for molecular targeted therapy 
Cancer is widely recognized as a multistep process involving the progressive 
accumulation of genetic and epigenetic abnormalities. Despite the extensive accumulation 
of multiple gain- and loss-of function mutations, in some cancers the inhibition of a single 
activated oncogenic protein or pathway provides a profound antitumor response. This 
phenomenon, coined ‘oncogene addiction’, is likened to an Achilles’ heel in which the 
cancer is reliant on the oncogene for maintenance of the malignant phenotype20–22. 
Evidence supporting oncogene addiction has been established in genetically engineered 
mouse models, mechanistic studies in human cancer cell lines, and in clinical trials with 
specific molecular targeted therapies in which non-tumor cells are minimally affected21,22. 
The seminal example is the use of Imatinib for the treatment of chronic myeloid leukemia 
(CML). The abnormal fusion gene, BCR-ABL, results from a chromosomal translocation 
found in more than 90% of CML patients. The expression of BCR-ABL is required for 
both induction and maintenance of leukemia in transgenic mouse models23.  The multi-
kinase inhibitor Imatinib was the first molecule shown to specifically inhibit BCR-ABL 
with high potency24. Imatinib is approved as a first line treatment for newly diagnosed 
CML patients25.  
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1.2.4 Late SV40 Factor (LSF) is an essential oncogene in HCC 
 Late SV40 Factor, commonly referred to as LSF and encoded by the gene TFCP2, 
is an evolutionarily conserved, ubiquitously expressed transcription factor (TF) that acts as 
both a transcriptional activator and repressor of multiple distinct viral and cellular 
promoters26,27. At the cellular level, LSF protein is upregulated in human HCC cell lines 
and is nearly undetectable in primary hepatocytes28. At the clinical level, HCC patient liver 
samples show an increased expression of LSF with a positive correlation to the BCLC stage 
of the disease28,29. Studies in mice solidify LSF as a bona fide oncogene in HCC. 
Overexpression of LSF in the non-tumorigenic HCC cell line HepG3 increases 
proliferative activity, colony-forming ability, anchorage-independent growth, and Matrigel 
invasion ability in vitro. Nude mice xenograft assays confirmed these tumor promoting 
properties in vivo. Control HepG3 clones do not form any tumors whereas LSF expressing 
clones generate large and aggressive tumors when implanted subcutaneously in the flanks 
of nude mice. Tumors show high LSF expression, high proliferation as measured by Ki-67 
expression, and increased angiogenesis as determined by CD31 expression. Multiorgan 
metastasis was observed when LSF expressing cells were injected into mouse tail veins. 
Conversely, inhibition of LSF function with a dominant negative LSF-DNA binding 
mutant (dnLSF) inhibited tumorigenicity. When clones were isolated of the aggressive 
HCC cell line QGY-7703 expressing dnLSF, they showed decreased proliferation, 
anchorage-independent growth, and invasion in vitro. In vivo, QGY-7703-dnLSF clones 
caused decreased tumorigenesis in nude mice xenografts.28 
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Proteins associated with LSF oncogenesis in HCC have been identified. The 
oncogene Astrocyte elevated gene-1 (AEG-1) is a key upstream regulator of LSF. Both 
AEG-1 and LSF are overexpressed in more than 90% of HCC patients.30 Resistance to the 
common chemotherapeutic drug 5-fluorouracil (5-FU) in HCC cells is mediated by AEG-
1 regulation of LSF31,32. The mechanism of 5-FU chemotoxicity is primarily through 
inhibition of thymidylate synthase (TS), a major cellular target gene of LSF.33 Thymidylate 
synthase encodes the rate limiting enzyme in production of deoxythymidine triphosphate 
(dTPP), which is required for progression through DNA synthesis (S) phase of the cell 
cycle. The Ras family small GTP binding protein (H-Ras) and neurogenic locus notch 
homolog protein 1 (Notch 1) have also been identified as cooperative upstream mediators 
of LSF29,34. Both human HCC cell lines and patient samples show overexpression of Notch 
1 and LSF proteins29,34. Treatment with DAPT, which blocks endogenous Notch 1 
activation, results in decreased expression of Notch 1 and downregulation of LSF. 
Constitutive activation of Notch 1 leads to increased levels of LSF protein. Co-expression 
of Notch 1 with H-Ras further augments LSF expression.34 These studies indicate that 
multiple mechanisms may contribute to LSF overexpression in HCC. 
 Downstream LSF target genes contributing to hepatocarcinogenesis have also been 
proposed. Thymidylate synthase (TS) activity is crucial for DNA replication and cellular 
proliferation. The gene encoding osteopontin (OPN) is robustly induced by LSF28. 
Osteopontin promotes every step of metastasis in multiple cancers including HCC and is a 
highly sensitive HCC biomarker35. Secreted OPN is induced by LSF, which in turn 
activates c-Met, an important mediator of epithelial to mesenchymal transition (EMT), 
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invasion, and metastasis via binding to CD44 receptors36. Snail1-induced fibronectin (FN1) 
requires LSF expression during EMT, increasing motility during invasion and 
metastasis37,38. Angiogenesis is mediated through LSF regulation of matrix 
metalloproteinase 9 (MMP-9), a component of the angiogenic switch39. Complement 
factors C7 (complement component 7) and CFH (complement factor H) have been 
suggested to stimulate LSF expression,  leading to the upregulation of the stemness factors 
Nanog, Oct4, Sox2, and c-Myc, which may increase cancer stemness40.  
As indicated above, there is an unmet clinical need for a molecularly targeted 
therapy for HCC. Late SV40 Factor is an appealing target for HCC therapy because it 
functions as an oncogene sufficient for tumor progression, and has been implicated in 
hepatocellular invasion, angiogenesis, and metastasis. The apparent role in liver cancer 
stem cells further makes LSF an attractive target, as cancer stem cells are thought to be 
responsible for not only cancer initiation but recurrence and drug resistance as well. 
 
1.2.5 Factor Quinolinone Inhibitors (FQIs) inhibit LSF-driven oncogene addiction 
 Small molecule dihydroquinolinone inhibitors of LSF, termed Factor Quinolinone 
Inhibitors (FQIs), were developed at Boston University (BU) in the laboratories of Scott 
Schaus and Ulla Hansen41. A high throughput fluorescence polarization assay of 110,000 
commercially available compounds assaying inhibition of in vitro LSF-DNA binding 
identified small molecule inhibitors of the LSF-DNA interaction. Nonspecific binders were 
ruled out by a secondary electromobility shift assay (EMSA) that tested the ability of the 
compounds to not only inhibit LSF, but also non-specific inhibition of protein-DNA 
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interactions of the unrelated transcription factors Sp1, Oct1, and E2F3. Compounds 
containing a dihydroquinolin-2(1H)-one core emerged from these screens as potent and 
selective inhibitors of in vitro LSF-DNA binding. The Schaus laboratory and BU-CMD 
have generated a library of compound analogs maintaining the dihyrdoquinolinone core 
modified with peripheral groups and enantioselectivities. Structure-activity relationship 
(SAR), discussed in more detail below, assessed cytoxicity of FQIs in a collection of 
carcinoma cell lines. The Hansen laboratory further demonstrated cytotoxic FQIs inhibit 
LSF transcriptional activity in an LSF dependent luciferase reporter assay. Analog FQI-1 
emerged from the SAR as the lead compound.41 LSF-DNA binding is inhibited by FQI-1 
in vitro in an EMSA, chromatin immunoprecipitation assay (ChIP), and DNA precipitation 
assay (DIP)41,42. The aggressive HCC cell line QGY-7703 undergoes rapid cell death with 
mitotic defects when treated with FQI-1, whereas both primary and immortalized 
hepatocytes remain unperturbed41.  
 Subcutaneous mouse xenografts with QGY-7703 derived tumors are profoundly 
inhibited by FQI-1 in vivo41. Tumor volume and weight were reduced approximately nine 
and four fold respectively upon treatment. Immunofluorescence of fixed tumor sections 
showed constant LSF protein levels in FQI-1 and vehicle control treated mice. However, 
the downstream LSF target OPN was abolished by FQI-1 treatment. This demonstrates that 
FQI-1 inhibits LSF activity as opposed to altering LSF expression levels. Liver sections 
treated with FQI-1 showed decreased vascularity and proliferation as evidenced by CD31 
and Ki-67 staining respectively. No general toxicity was evident in the FQI-1 treated mice, 
as assayed by lack of changes in body weight, feeding, grooming, posture, and general 
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behavior. Histopathology of tissues/organs showed no discernable toxicity of FQI-1. 
Levels of liver enzymes and proteins in the blood were also unaffected, indicating normal 
liver function.41 
 Chemotherapeutic efficacy of FQI-1, and an unsaturated FQI-2 analog, against an 
endogenous HCC mouse model demonstrates the therapeutic utility of FQIs (Figure 1.4)43. 
In this model, A1b/c-myc mice treated with diethylnitrosamine spontaneously develop 
HCC.  The number of tumor nodules significantly decreased with FQI treatment, and liver 
weight was returned to non-tumor levels. Histopathology of the livers showed normal 
hepatic architecture for FQI treated mice whereas control mice showed features of HCC. 
Immunohistochemical analysis of tumors revealed increases in the HCC marker α-
fetoprotein (AFP), proliferation marker proliferating cell nuclear antigen (PCNA), and 
angiogenesis marker CD31 in control animals. The LSF target genes OPN and TS were 
decreased in FQI treated mice in comparison to vehicle control. The level of enzymes 
indicating liver damage were significantly decreased in FQI treated mice, and no obvious 
signs of toxicity was observed for either FQI treatment groups.43   
These results demonstrate that LSF is a promising oncogenic molecular target for 
the treatment of HCC. The in vivo mice studies fit the definition of oncogene addiction, 
whereby both subcutaneous HCC xenografts and endogenous HCC tumors failed to 
maintain tumorigenicity by overcoming addiction to LSF with FQI treatment. 
Herein, derivatives of the dihydroquinolinone core are shown to be potent inhibitors 
of HCC cell proliferation and luciferase reporter assays directed by the LSF subfamily of 
transcription factors. Direct LSF-FQI target engagement in a cellular setting is 
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demonstrated for the first time using the Cellular Thermal Shift Assay (CETSA). Finally, 
the lead compound, FQI-34, is shown to be a highly potent and selective inhibitor of the 
LSF subfamily of transcription factors, leading to aberrant mitosis in HCC cells.  
Pharmacokinetic and rat tolerability studies indicate FQI-34 is a promising candidate for 
HCC therapy. 
 
 
Figure 1.4 Dihydroquinolinones FQI-1 and FQI-2 inhibit endogenous HCC in Alb/c-myc mice  
A) Upper: representative photograph of livers of the indicated group at the end of the experiment. Lower: 
representative Hematoxylin and Eosin stained liver sections of the indicated group at the end of the 
experiment. Magnification: 400X. B) Liver weight of the mice in the treatment groups. C) Number of liver 
nodules in the indicated group. D) Serum levels of aspartate aminotransferase (AST), alanine 
aminotransferase (ALT) and alkaline phosphatase (Alk Phos) in the indicated treatment groups. For B-D, n 
= 10 in each group. The data represent mean ± SEM. *:p < 0.01. E) Immunohistochemical analysis of the 
indicated proteins in the liver sections of the indicated groups. Magnification: 400X. Images taken from 
Rajeskaran, et al (ref 43) 
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1.3 RESULTS AND DISCUSSION 
1.3.1 Structure-activity-relationship (SAR) of dihydroquinolinone inhibitors 
The dihydroquinolinone library structure-activity relationship (SAR) analysis was 
directed by two in vitro assays. A primary colorimetric MTS cell proliferation assay in 
QGY-7703 cells ranks compounds by antiproliferative potency. A secondary LSF driven 
luciferase reporter assay assesses inhibition of LSF transcriptional activity. 
Dihydroquinolinone library synthesis was conducted in the Schaus Laboratory (by John 
Kavouris) or in the BU-CMD (by Lauren Brown). The commercial MTS cell viability 
assay contains a tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) which is bioreduced in 
metabolically active cells to produce a colored formazan product. Maximum formazan 
absorbance at 490 nm was measured for both vehicle control (1% DMSO) and FQI treated 
cells after 72-hour treatment in 96-well plates. Growth inhibition was calculated as the 
percent decrease from the growth of the control cells and was plotted against increasing 
FQI compound concentrations to generate dose-response curves (Appendix 2). The extent 
to which FQIs inhibited cell proliferation was quantified from dose-response curves as the 
concentration that caused 50% growth inhibition (GI50). 
The original SAR cell proliferation assay was conducted largely in NIH-3T3 mouse 
fibroblasts, the human small cell carcinoma line A549, and the human cervical cancer cell 
line HeLa44,45. Only FQIs with low μM GI50s were further tested in the aggressive HCC 
cell line QGY-770344.  The structure of the lead compound FQI-1, the achiral counterpart 
FQI-2, and the active (S)-(-)-FQI-1 and inactive (R)-(+)-FQI-1 enantiomers are shown in 
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Figure 1.5.  The lead compound FQI-1 had a GI50 of 1.3 μM in QGY-7703 cells. The achiral 
FQI-2 showed a GI50 of 0.9 μM. The (S) enantiomer had a GI50 of 0.8 μM while the (R) 
enantiomer was nearly inactive with a GI50 of ~20 μM. Poor solubility and low yields 
barred FQI-2 and (S)-(-)-FQI-1, respectively, from being the lead compounds. For my 
studies, cell proliferation assays were conducted in QGY-7703 cells to rank FQIs by their 
antiproliferative activity in the HCC setting. The goal of the SAR was to fine-tune the FQI-
1 structure for sub-micromolar potencies and increased aqueous solubility. 
 
 
Figure 1.5 Structures of the lead dihydroquinolinone compounds 
Dihydroquinolinone FQI-1 emerged as the lead compound from the original SAR. The unsubstituted FQI-2 
showed increased activity, but solubility was decreased 2-fold. The (S) enantiomer showed increased 
antiproliferative activity and the (R) enantiomer was inactive.  
 
The amide portion of the quinolinone core was previously found optimal for 
activity in NIH-3T3, A549, and HeLa cell lines44. These substitutions were not tested in 
QGY-7703 cells. To begin, I tested these substitutions in QGY-7703 cells to validate the 
contribution of the amide moiety (Table 1.1). Oxygen substitution of the nitrogen (FQI-24) 
completely abolished activity. This was also observed in NIH-3T3, A549, and HeLa cells. 
Methylation of the amide (FQI-25) and deoxygenation to the tetrahydroquinoline (FQI-27) 
led to approximately a 17- and 23-fold reduction in potency, respectively. This diminished 
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potency was greater than that observed in the other cell lines, which showed about a 5-fold 
reduction in potency for each modification across cell lines. A series of triazole 
substitutions (Tri-FQIs) was also previously explored, with the aim of improving both 
antiproliferative potency and aqueous solubility by replacing the amide with a common 
bioisostere44. The Tri-FQIs produced about a 2-fold increase in solubility, however the 
potency was less than their amide counterparts. I further found substitution with a tetrazole 
moiety ablated activity (Tetra-FQI-1, Table 1.1). 
 The only amide modification to demonstrate significant improvement in activity 
was replacement of oxygen with sulfur (Thio-FQI-1, Table 1.1)44. Sulfur has a larger 
atomic radius than oxygen, imparts lower electronegativity and lower ionization energy to 
the molecule, and is less polar than the corresponding carbonyl46. As will be discussed in 
section 1.3.5, although improvement in potency was achieved, solubility of the less polar 
compound was drastically reduced. Continued attempts to modify the amide region proved 
ineffective (Table 1.1). Replacement of the carbonyl with methyl- or ethyl aniline (FQI-30 
and FQI-31) reduced potency about 10- and 13-fold respectively. Conversion to a 2-Cl 
quinoline derivative (FQI-23) reduced potency 6-fold. A cyclic urea derivative (FQI-Urea) 
reduced proliferative activity 5-fold.   
The results of the original SAR suggested the O-alkyl side chain on the phenyl ring 
at the C4 position was critical for FQI-target engagement44,45. The alkoxy side chain length 
was altered from one to four carbons and positioned either ortho or para to the 
dihyrdoquinolinone core. Moving to the para-position completely abolished activity. 
Carbon length also proved to be important for antiproliferative activity. Methoxy 
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substitution lowered activity, likely due to too much free rotation about the C4 bond. 
Butoxy and tert-butoxy substitution diminished inhibition presumably from crowding the 
binding pocket. Ethoxy and propoxy substitution were found to be optimal length. Analysis 
of the stereochemistry of FQI-1, FQI-2 and the separated FQI-1 enantiomers further 
suggested the ring makes contact with its biological target. Three-dimensional analysis of 
the two enantiomers and the achiral FQI-2 predicted the active (S) enantiomer and the 
unsaturated FQI-2 adopt the same orientation. The predicted orientation places the C4-
phenyl ring in the opposite plane of the inactive (R) enantiomer.41,44,45  
Given the critical substitution and orientation of the C4 phenyl ring, my work 
focused on further ring substitution. The ethoxy group remained in the ortho position and 
additional substitutions were made to the para position of the dihydroquinolinone core 
(Table 1.2). Substitution with a fluorine (FQI-F) gave near equal potency to FQI-1. 
Fluorine is generally viewed as a classic bioisostere of hydrogen. Steric parameters for 
hydrogen and fluorine are similar, their van der Waal’s radii being 1.2 and 1.35 Å, 
respectively.47 Substitution with chlorine (FQI-Cl) showed a great improvement in potency 
with a 310 nM GI50 while the larger bromine (FQI-Br) substitution had a 650 nM GI50. 
Substitution with a dimethylamino group (FQI-34) had a 467 nM GI50. The FQI-34 
analogue was separated by chiral chromatography to the corresponding (R) and (S) 
enantiomers. As was seen with the separation of FQI-1 enantiomers, growth inhibition 
revealed enantiomeric specificity, in that the (R)-FQI-34 was less potent than the racemate, 
whereas (S)-FQI-34 showed increased potency.  
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Larger substituted and unsubstituted pentane additions (FQI-32 and FQI-33) as well 
as a modified PEG group (PEG-FQI) showed no inhibition at 10 μM. These results further 
suggest this ring makes critical contacts with its biological target. Combined substitutions 
were not additive. Neither Tri-FQI-1-Cl or Thio-FQI-Cl showed antiproliferation activity 
greater than FQI-Cl or Thio-FQI-1. This was likely due to poor solubility. The calculated 
LogS values were -4.12 and -5.38, respectively (calculated via VCCLAB, Virtual 
Computational Chemistry Laboratory, https://www.vcclab.org). Analysis of the original 
SAR demonstrated LogS values correlated well with inhibitory capability45. The larger, i.e. 
less negative, the value for LogS, the more soluble and active the compound45.  
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Cell Line GI50 (μM) Cell Line GI50 (μM)
FQI-1
Compound Compound
FQI-27
FQI-25
FQI-24
Tetra-FQI-1
Tri-FQI-1
Thio-FQI-1
FQI-Urea
FQI-31
aReference 44
QGY-7703 23.4
NIH-3T3 17.1
QGY-7703 17.2
ND= Not determined
QGY-7703 6.9
NIH-3T3 18.0 NIH-3T3 ND
QGY-7703 17.5
NIH-3T3 >200 NIH-3T3 20.2
QGY-7703 >200 
QGY-7703 >145 FQI-30 QGY-7703 14.3
NIH-3T3 >145 NIH-3T3 6.3
NIH-3T3a 4.3 NIH-3T3 >25
QGY-7703a 1.5 FQI-23
3.8 NIH-3T3a 0.4
QGY-7703 8.3
Table 1.1 GI50 values for SAR amide modifications
QGY-7703a 1.3 QGY-7703a 0.3
NIH-3T3a
21 
 
 
 
   
Cell Line GI50 (μM) Cell Line GI50 (μM)
FQI-F
Table 1.2 GI50 values for SAR modifications para  to the C4 phenyl ring of the 
dihydroquinolinone 
Compound Compound
QGY-7703 1.5 FQI-32 QGY-7703 5.5
NIH-3T3 3.4 NIH-3T3 ND
FQI-Cl QGY-7703 0.3 FQI-33 QGY-7703 >10
NIH-3T3 1.8 NIH-3T3 ND
FQI-Br QGY-7703 0.7 PEG-FQI QGY-7703 >10
NIH-3T3 1.8 NIH-3T3 ND
FQI-34 QGY-7703 0.5 (S)-FQI-34 QGY-7703 0.3
NIH-3T3 0.7 NIH-3T3 0.6
(R)-FQI-34 QGY-7703 3.8 FQI-35 QGY-7703 1.8
NIH-3T3 5.9
ND= Not determined
NIH-3T3 ND
Tri-FQI-1-Cl
QGY-7703 3.2
NIH-3T3 ND
22 
 
 
 
1.3.2 Dihydroquinolinone inhibition of LSF transcriptional activity  
 The second tier of the SAR utilizes a dual luciferase reporter assay system to 
determine dihydroquinolinone ability to inhibit LSF transcriptional activity. Firefly 
luciferase activity derived from a LSF-dependent reporter construct is measured alongside 
the transcriptional activity of an internal control, a renilla luciferase gene driven by the 
constitutively active Herpes simplex virus thymidine kinase (HSV-tk) promoter. The 
reporter assay is executed in NIH-3T3 mouse fibroblast cells, since NIH-3T3 cells express 
a low level of LSF protein. Additional LSF is expressed through addition of a constitutive 
EF1α promoter driven LSF construct. Immunoblot analysis showed total LSF protein 
expression remained steady with FQI treatment (Figure 1.6). Relative changes in the 
expression of firefly luciferase reporter activity correlate to changes in the transcriptional 
activity of LSF. Quantitation of luminescent signal from each of the bioluminescent 
reporter enzymes is accomplished with a commercial kit that selectively discriminates 
between the two bioluminescent reactions. The ratio of firefly luciferase activity to that of 
renilla luciferase is normalized to the ratio from the vehicle control and indicates relative 
LSF transcriptional activity. The value of the internal renilla luciferase control is twofold. 
The internal control minimizes inherent experimental variabilities such as differences in 
the number and health of the cells as well as the efficiency of cell transfection and lysis. 
The internal control can additionally identify off-target inhibition of the HSV-tk promoter 
activity. I observed essentially invariable renilla luciferase signals, indicating no off-target 
effects of dihydroquinolinone treatment. Thus, reduction in firefly luciferase signal is due 
to dihydroquinolinone inhibition of LSF transcription activity.  
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Figure 1.6 LSF protein levels in FQI-1 treated reporter assay lysates 
LSF protein levels are essentially constant in vehicle control (DMSO) and each treatment group. This 
demonstrates consistent transfection of LSF protein, and decrease of luciferase activity is a consequence of 
inhibition of activity and not decrease of LSF protein. Represents a single experiment. 
 
 
The IC50 (the concentration at which LSF transactivation was inhibited 50%) was 
determined for each dihydroquinolinone (Table 1.3). A positive correlation between 
dihydroquinolinone induced antiproliferation (GI50) and inhibition of LSF-DNA binding 
activity (IC50) has been demonstrated with previous FQI analogs44. This positive 
correlation was maintained with the new dihydroquinolinones I tested. Comparison of the 
GI50 in NIH-3T3 cells and reporter assay IC50 values show a strong correlation with R value 
of 0.92 (Figure 1.7A). The GI50 values in QGY-7703 cells also show a correlation to LSF 
inhibition IC50 values (Figure 1.7B). The correlation is not as strong in the QGY-7703 cells 
as seen in the NIH-3T3 cells, with R value of 0.76. However, the transcriptional assay is 
performed in NIH-3T3 cells, and the hepatocellular QGY-7703 cells are more sensitive to 
dihydroquinolinone inhibitor treatment than the non-cancerous mouse fibroblasts which 
express less LSF protein. The overall positive correlation between IC50 and GI50 suggests 
antiproliferative phenotypes induced by FQIs result from targeting LSF transcriptional 
activity.  
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Figure 1.7 Correlation between cell growth and LSF-DNA binding inhibition 
MTS cell proliferation GI50 values versus LSF-directed firefly luciferase reporter IC50 values for active FQI 
analogs (labeled). A) NIH-3T3 cells. B) QGY-7703 cells. The linear relationship suggests the 
antiproliferative effects are a consequence of inhibition of LSF transcriptional activity. 
Name IC50 (μM) Name IC50 (μM) Name IC50 (μM) Name IC50 (μM)
FQI-1a 2.1 FQI-2a 0.7 (S)-(-) -FQI-1a ~0.9 (R)-(+) -FQI-1a >10
Tri-FQI-1a ~4.7 Thio-FQI-1 ~0.5 FQI-F ~2.9 FQI-Cl 1.7
FQI-Br 1.8 FQI-34 0.7 (S)-(-) -FQI-34 0.6 (R)-(+) -FQI-34 >5
aReference 44
Table 1.3 IC50 values for LSF driven luciferase reporter assay
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1.3.3 Dihydroquinolinones inhibit LSF subfamily of transcription factors 
 Late SV40 Factor is a member of a highly conserved and ancient family of 
transcription factors consisting of two branches: the LSF subfamily, and the Grainyhead 
(GRH) subfamily26. No apparent protein sequence homology exists outside of these 
families. The LSF subfamily includes LSF, LBP1a and b (proteins encoded by two splice 
variants of the same gene), and LBP9. The mammalian GRH subfamily includes GRHL1, 
GRHL2, and GRHL3. The DNA binding regions in the subfamilies show a large degree of 
conservation, but each subfamily has distinct transcriptional targets26. The LSF subfamily 
recognizes a conserved CNRG-N6-CNR(G/C) motif. The GRH subfamily binds a similar 
single CNRG motif 26,48. The two subfamilies can be distinguished from each other by their 
distinctive oligomerization domains and oligomerization behaviors. The LSF members are 
dimers in solution, and require tetramerization to bind DNA49–51. The GRH members are 
dimers in solution, and bind DNA as a dimers48,52. Domain analysis of LSF protein will be 
discussed in more detail in Chapter 3. Each subfamily can interact with members of its own 
subfamily, but cannot cross oligomerize26. 
 Trevor Grant (Hansen Laboratory) previously tested FQI-1 activity in luciferase 
driven reporter assays against LSF, LBP1a, LBP1b, LBP9, GRHL1, GRHL2, and GRHL3. 
The dihydroquinolinone FQI-1 only inhibited the activity of the LSF subfamily 
(unpublished, data not shown). It should be noted that the reporter assay discussed in 
section 1.3.2 utilized LSF expressed from a vector that uses a constitutive EF1α promoter. 
The restriction sites needed for cloning the family members prevented use of the pEF1α 
vector. cDNAs encoding the indicated proteins were instead cloned into a pcDNA vector 
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that uses a constitutive CMV promoter/enhancer. The same luciferase reporter gene that 
was used with the EF1α promoter-driven LSF was used with each CMV promoter-driven 
family member. The construct for the luciferase reporter gene contains 4 consecutive LSF 
binding sites that can be bound by the LSF and the GRH subfamilies. Firefly luciferase 
signal remains at background levels if LSF or GRH proteins are not coexpressed in the 
system.  
 I tested the effect of dihydroquinolinones Tri-FQI-1, Thio-FQI-1, FQI-Cl, and 
FQI-34 in reporter assays against LBP1a, LBP9, and GRHL-1. The CMV-promoter driven 
LSF was tested as well. Promoter strength differences resulted in slightly different curve 
shapes and IC50 values between EF1α and CMV promoter driven LSF expression. Trends 
remained constant despite differences in curve shape. The dihydroquinolinones selectively 
inhibited the activity of the LSF subfamily with near equal potency but did not affect 
GRHL1 transcriptional activity (Figure 1.8).  
 
1.3.4 Development of dihydroquinolinone target engagement assay 
 The efficacy of a therapeutic is dependent on a drug binding its intended target. 
Transcription factors (TF) have historically been considered “undruggable”, with the 
exception of nuclear hormone receptors. Nuclear receptors contain a defined ligand binding 
pocket and are activated by natural ligands such as retinoic acid-, glucocorticoid-, estrogen- 
or androgen-receptors.53 Transcription factors were deemed undruggable because they do 
not contain a clearly defined binding pocket. Their natural binding ligand is a cognate DNA 
sequence which requires binding to a generally large surface on the TF53.   
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Figure 1.8 Dihydroquinolinones selectively inhibit LSF subfamily of transcription factors, but not the 
GRH subfamily  
Protein-dependent firefly luciferase reporter activities in NIH-3T3 cells. Cells were transfected with a 
luciferase reporter gene containing LSF/GRH binding sites, an internal renilla luciferase control reporter, and 
either an LSF, LBP1a, LBP9, or GRHL1 expression construct. Two LSF expression constructs were used; 
an EF1α-LSF construct or CMV-LSF construct. LBP1a, LBP9, and GRHL-1 were all driven by CMV 
promoters. For each concentration of FQI, firefly luciferase activities were normalized to activity in the 
absence of FQIs. Each of the five FQIs was tested independently. FQI-1 was tested by Trevor Grant (Hansen 
Laboratory). Legend shown on bottom right. Averages with SD derived from 3 independent experiments. 
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Despite these challenges, modulation of TF activity has recently shown to be 
successful with small molecule TF inhibitors making their way into the clinic for cancer 
treatment54. Alteration of TF activity can be achieved via direct interaction with the TF 
itself, inhibition of protein-protein interactions (PPIs) of the transcription factor complex, 
indirect alteration through binding chromatin remodeling/epigenetic reader proteins 
essential for TF-DNA access, or competitive binding to the TF’s recognition DNA 
sequence55. The dihydroquinolinones were discovered in in vitro methods that imply 
inhibition is not through an indirect mechanism. To date, no unequivocal evidence showed 
direct target engagement between the dihydroquinolinones and LSF.  
The cellular thermal shift assay (CETSA) is a biophysical assay developed by 
Molina et al (2013) based on the long-known fact that a protein complexed to a ligand is 
typically resistant to heat-induced unfolding56. This phenomenon has been used to 
systematically screen recombinant proteins against potential inhibitors in a thermal shift 
assay57. Thermally induced unfolding experiments with purified protein produce distinct 
melting curves. These melting curves typically shift to a higher temperature when a ligand 
binds and stabilizes its target protein.57 The CETSA method broadens the studies of target 
engagement of drug candidates to a cellular context, including cell lysates, whole cells, and 
tissue samples. The method is based on the discovery that when heated in cells many 
proteins unfold and precipitate. The amount of remaining soluble protein in the cell 
correlates with the amount of protein that remains folded. The remaining soluble protein is 
isolated after the heating step and quantified to generate a distinct CETSA melting curve. 
Addition of a ligand that binds the targeted protein results in a shift to higher temperatures 
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of the melting curve demonstrating proof of compound and target protein interaction. 
Thermal shifts of proteins in a cellular setting is representative of the true target 
environment, taking into account the presence of high concentrations of all cellular 
proteins, lipids and biomolecules.56,58,59 
In this work, the CETSA method was applied to cell lysates from the LSF 
overexpressing HCC cell line QGY-7703. Figure 1.9 shows the general CETSA method 
developed. The CETSA protocol involves three principle steps after the lysate has been 
collected and incubated with ligand. The first step is a temperature exposure step. The 
lysate is heated for 5 minutes at distinct temperatures followed by a 5-minute cool-down 
on ice. The soluble protein fraction is isolated in the next step by centrifugation at high 
force. The isolated proteins are predominantly those that remain folded after the heating 
step. In the final step, isolated soluble protein is detected via immunoblot. Quantitation of 
immunoblot generates thermal-melt curves.  
 
 
 
Figure 1.9 Dihydroquinolinone CETSA Protocol 
In the developed CETSA method, QGY-7703 cells are first lysed in RIPA buffer by 3-freeze/thaw cycles. 
Lysates are then incubated with an excess of FQI compound for 30 minutes. After 30 minutes, samples are 
aliquoted and heated individually for 5 minutes at a range of temperatures to generate melt/shift curves. After 
5-minute on ice, the soluble fraction is isolated by centrifugation at top speeds. The amount of remaining 
soluble protein in the sample is detected via western blot. Quantitation of immunoblots generates thermal-
melt curves. 
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The dihydroquinolinones were analyzed for thermal stabilization of LSF in HCC 
cell lysates. Figure 1.10 shows representative immunoblots of at least 3 biological 
replicates and resulting quantified thermal shift data. Active dihydroquinolinones showed 
thermal denaturation of LSF at higher temperatures than vehicle control. The inactive 
dihydroquinolinones (R)-(+)-FQI-1 and (R)-(+)-FQI-34 did not show stabilization of LSF 
protein. Area-under-curve (AUC) analysis was performed for each thermal shift dataset 
and used to statistically confirm differences in binding curves. The active FQI compounds 
demonstrated statistically larger AUCs than that of the vehicle control, confirming direct 
FQI-LSF target engagement. As further proof of direct target binding, vehicle control 
treated lysates demonstrate LSF with a Tm50 (the temperature at which 50% of proteins are 
precipitated by thermal denaturation) of 55.0°C. In contrast, the active 
dihydroquinolinones all showed Tm50s for LSF with at least a 2°C magnitude increase 
(Table 1.4). 
 
 
 
 
Compound: DMSO FQI-1 FQI-2 (R)-(+) -FQI-1 (S)-(-) -FQI-1 Tri-FQI-1
Tm50 °C: 55.0 59.1 59.2 55.7 59.2 60.7
ΔTm50 °C: NA 4.1 4.2 0.7 4.2 5.7
Compound: Thio-FQI-1 FQI-F FQI-Cl FQI-Br FQI-34 (R)-(+) -FQI-34
Tm50 °C: 58.4 57.9 58.6 58.0 62.9 56.1
ΔTm50 °C: 3.4 2.8 3.6 3.0 7.8 1.1
Compound: (S)-(-) -FQI-34
Tm50 °C: 59.7
ΔTm50 °C: 4.7
Table 1.4 LSF Cellular thermal shift assay Tm50 values
31 
 
 
 
 
50 52 54 56 58 60 62 64
0
50
100
150
FQI-1
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
FQI-1
50 52 54 56 58 60 62 64
0
50
100
150
FQI-2
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
FQI-2
50 52 54 56 58 60 62 64
0
50
100
150
(R)-(+)-FQI-1
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
(R)-(+)-FQI-1
50 52 54 56 58 60 62 64
0
50
100
150
(S)-(-)-FQI-1
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
(S)-(-)-FQI-1
50 52 54 56 58 60 62 64
0
50
100
150
Tri-FQI-1
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
Tri-FQI-1
50 52 54 56 58 60 62 64
0
50
100
150
Thio-FQI-1
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
Thio-FQI-1
 
32 
 
 
 
50 52 54 56 58 60 62 64
0
50
100
150
FQI-F
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
FQI-F
50 52 54 56 58 60 62 64
0
50
100
150
FQI-Cl
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
FQI-Cl
50 52 54 56 58 60 62 64
0
50
100
150
FQI-Br
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
FQI-Br
50 52 54 56 58 60 62 64
0
50
100
150
FQI-34
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
FQI-34
50 52 54 56 58 60 62 64
0
50
100
150
S-(-)-FQI-34
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
S-(-)-FQI-34
50 52 54 56 58 60 62 64
0
50
100
150
R-(+)-FQI-34
Temperature C
R
e
la
ti
v
e
 B
a
n
d
  
In
te
n
s
it
y
DMSO
R-(+)-FQI-34
 
 
D
M
SO
 
FQ
I-1
 
FQ
I-2
 
(R
)-
(+
)-F
Q
I-1
(S
)-
(-)
-F
Q
I-1
Tr
i-F
Q
I-1
Th
io
-F
Q
I-1
FQ
I-F
FQ
I-C
l
FQ
I-B
r
FQ
I-3
4
(R
)-
(+
)-F
Q
I-3
4
(S
)-
(-)
-F
Q
I-3
4
0
500
1000
1500
M
e
a
n
  
A
U
C

 S
E
** **
ns ns
**
**
****
**
**
*
*
**
 
Figure 1.10 (continued from page 31) Dihydroquinolinones interact with LSF in HCC cell lysates 
CETSA was performed on QGY-7703 cell lysates as described in the Materials and Methods section. 
Representative Western blots (at least 3 biological replicates) are shown on page 31. The intensity of the LSF 
bands was quantified using Image J software. Quantification of the CETSA Western blots (N≥3), indicating 
means ± S.E.M, are shown on pages 31-32. Calculated area-under-the-curve (AUC) ± S.E.M for each 
compound are shown on page 32. Statistical significance between FQI treatment and control (DMSO) was 
determined by an unpaired Student's t test difference: ***p <0.001, **p<0.01, ns p>0.05 
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The CETSA method demonstrates shifts in the thermal denaturation curves that 
confirm drug binding. At saturating drug concentrations, the Tm50 of these shifts can be 
used to directly rank the relative affinity of compounds to their target in the cell59. In the 
case of the dihydroquinolinones, however, poor solubility in the lysis buffer disabled a 
robust correlation between Tm50 (or AUC) and IC50 or GI50. Efficient cellular lysis of QGY-
7703 cells is achieved in RIPA buffer. For the CETSA experiments, QGY-7703 cells were 
lysed in a modified RIPA buffer, using minimal concentrations of detergents to prevent 
denaturation of proteins upon lysis. In an attempt to achieve saturation, 500 μM of 
compound was used in each CETSA assay. A cloudy precipitate was seen upon addition 
of dihydroquinolinone to the cellular lysate. Although most compounds went into solution 
during the 30-minute room temperature incubation, Thio-FQI-1 and the halogenated FQIs 
failed to fully dissolve in the RIPA buffer. It is known that both thionyl and halogen groups 
can decrease the aqueous solubility and increase lipophilicity of compounds. When first 
tested using the normal protocol, Thio-FQI-1 showed minor stabilization of LSF (Figure 
1.11, Tm50 55.4); upon heating to 37°C, target engagement was confirmed (Figure 1.10). 
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Figure 1.11 LSF CETSA results using room temperature incubation with Thio-FQI-1  
Left: Western blot for CETSA analysis. Right: Quantification of CETSA Western blots (DMSO N≥3, Thio-
FQI-1 N=1), showing mean ± S.E.M for the control data.   
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The dihydroquinolinones were also analyzed for thermal stabilization of the LSF 
paralog LBP1a/b. For these assays, FQI-1, FQI-2, (R)-(+)-FQI-1 and (S)-(-)-FQI-1, Tri-
FQI-1, Thio-FQI-1, FQI-Cl and FQI-34 were tested. As with LSF, active 
dihydroquinolinones positively stabilized LBP1a/b whereas the inactive (R)-(+)-FQI-1 
compound did not. LBP1a/b in cell lysates treated with vehicle showed a Tm50 of 63.2° 
(Table 1.5). Note that the LBP1a/b antibody used for immunoblot analysis is more robust 
than the LSF antibody. This might account for the apparently more dramatic thermal shifts 
for LBP1a/b than for LSF. Figure 1.12 shows representative Western blots of at least 3 
biological replicates, as well as their quantitation, and AUC analysis.  
 
 
 
Compound: DMSO FQI-1 FQI-2 (R)-(+) -FQI-1 (S)-(-) -FQI-1
Tm50 °C: 63.2 68.3 69.4 63.9 67.2
ΔTm50 °C: NA 5.1 6.2 0.6 4.0
Compound: Tri-FQI-1 FQI-Cl Thio-FQI-1 FQI-34
Tm50 °C: 67.7 67.7 68.4 68.2
ΔTm50 °C: 4.5 4.5 5.2 5.0
Table 1.5 LBP1a/b Cellular thermal shift assay Tm50 values
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Figure 1.12 (continued from page 35) Dihydroquinolinones interact with LBP1a/b in HCC cell lysates 
CETSA was performed on QGY-7703 cell lysates as described in the Materials and Methods section. 
Representative Western blots (at least 3 biological replicates) are shown on page 35. The intensity of the 
LBP1a/b bands was quantified using Image J software. Quantification of the CETSA Western blots (N≥3), 
indicating means ± S.E.M, are shown on page 35. Calculated area-under-the-curve (AUC) ± S.E.M for each 
compound are shown on page 36. Statistical significance between FQI treatment and control (DMSO) was 
determined by an unpaired Student's t test difference: ***p <0.001, **p<0.01, ns p>0.05 
 
 
The CETSA method was also used to validate the lack of binding of 
dihydroquinolinones to GRHL1 in HCC cellular lysates. The dihydroquinolinones FQI-1, 
FQI-2, Tri-FQI-1, and FQI-34, which showed large and consistent shifts in the LSF and 
LBP1a/b CETSAs, were chosen to probe GRHL1 binding. Concomitant with results from 
the luciferase reporter assay, the active dihydroquinolinones did not engage GRHL1. In the 
vehicle-treated extracts, GRHL1 had at Tm50 of 64.3°C. All dihydroquinolinones tested 
shifted the Tm50 of GRHL1 less than a 1°C from that of the control (Table 1.6). Figure 1.13 
shows representative Western blots of at least 3 biological replicates, as well as 
quantitation, and AUC analysis.  
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Compound: DMSO FQI-1 FQI-2 Tri-FQI-1 FQI-34
Tm50 °C: 64.3 63.4 64.5 65.0 65.1
ΔTm50 °C: NA -0.8 0.2 0.8 0.8
Table 1.6 GRHL1 Cellular thermal shift assay Tm50 values
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Figure 1.13 (continued from page 37) Dihydroquinolinones do not interact with GRHL1 in HCC cell 
lysates 
CETSA was performed on QGY-7703 cell lysates as described in the Materials and Methods section. 
Representative Western blots (at least 3 biological replicates) are shown on page 37. The intensity of the 
GRHL1 band was quantified using Image J software. Quantification of the CETSA Western blots (N≥3), 
indicating means ± S.E.M, are shown on page 37. Calculated area-under-the-curve (AUC) ± S.E.M for each 
compound are shown on page 38. Statistical significance between FQI treatment and control (DMSO) was 
determined by an unpaired Student's t test difference: ns p>0.05 
 
 
Overall, the CETSA method demonstrated for the first time that active 
dihydroquinolinones directly bind LSF and LBP1a/b in HCC cell lysates. Furthermore, 
FQIs are selective to the LSF subfamily and are excluded from binding to the closely 
related GRH subfamily. Unfortunately, compound solubility issues prevented correlation 
between binding affinities in the transactivation assays to thermal shifts determinations in 
the CETSAs. The next section discusses kinetic solubility assay of the dihydroquinolinones 
in both RIPA and PBS (phosphate-buffered saline) buffer. 
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1.3.5 Kinetic turbidity solubility assays 
 Kinetic solubility of the dihydroquinolinones was first determined in RIPA cell 
lysate buffer via a turbidimetric method outlined by Kerns and Di (2005)60. In this method, 
compound is dissolved in vehicle control (DMSO) and added to buffer in a 96-well plate. 
The absorbance at 620 nm is observed after an incubation period. The FQI compounds do 
not absorb light at 620 nm. Any absorbance reading over 0.01 units is a direct result of 
precipitation due to light scattering. In parallel to the CETSA experiment, compounds were 
diluted in DMSO to make a 50 mM stock. The 50 mM stock was added to RIPA buffer to 
generate a final concentration of 500 μM and 1% DMSO. Compounds were incubated at 
room temperature for 30 minutes prior to taking absorbance readings. Figure 1.14 validates 
that Thio-FQI-1 largely precipitated in RIPA buffer, as well as each of the halogenated 
dihydroquinolinones. Additionally, the unsaturated FQI-2 analog showed precipitation.     
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Figure 1.14 Kinetic turbidity solubility assay under CETSA conditions 
500 μM of the indicated dihydroquinolinone was incubated with RIPA buffer in a 1% DMSO final 
concentration. Absorbance at 620 nm was taken after 30 minutes.  Mean absorbance (N=7)    S.D. shown.  
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Solubility is not only important for in vitro bioassays, but is also imperative for in 
vivo bioavailability. Dihydroquinolinone FQI-1 was not bioavailable, with merely 0.7% 
calculated bioavailability in rats44. The turbidic solubility method was performed with 
dihydroquinolinones under physiological conditions. In this method, solid compound was 
first dissolved in DMSO for a 30 mM final stock concentration. The stock solution was 
serially diluted into buffered (1x PBS, pH 7.2) wells of a 96-well plate. The final DMSO 
percent was kept to 1%. After a 2-hour incubation period at 37°C, the absorbance at 620 
nm was measured. The maximum concentration, when dissolved, lies below the 0.01 
absorbance unit mark (Figure 1.15). The halogenated FQIs and Thio-FQI-1 precipitated in 
the 20-50 μM range; FQI-1 precipitated in the 75-100 μM range; FQI-34 had increased 
solubility and precipitated in the 150-200 μM range; and Tri-FQI-1 proved to be the most 
soluble with precipitation in the 200-300 μM range. It should be noted that initial trials 
with FQI-34 produced inconsistent readings. Trials ranged from precipitation between 75 
and 200 μM (data not shown). NMR analysis (data not shown, analysis by John Kavouris) 
showed that FQI-34 is hygroscopic. Water content from different preparations ranged from 
3-9%. The solubility was consistently in the 150-200 μM range when ball-milled, oven 
dried material was used. 
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Figure 1.15 Kinetic turbidity solubility assay under physiological conditions 
Turbidity assay in PBS buffer at pH 7.2 (see Materials and Methods for details). Absorbance readings above 
0.01 units (dashed line) signify the precipitation point. Halogenated FQIs (FQI-F, FQI-Cl, and FQI-Br), and 
Thio-FQI-1 precipitate in the 20-50 μM range. FQI-1 precipitates in the 75-100 μM range. FQI-34 
precipitates in the 150-200 uM range, and Tri-FQI-1 precipitates in the 200-300 μM range. Mean absorbance 
(N=7)    S.D. shown. 
 
 
 
1.3.6 Dihydroquinolinone FQI-34 induces a mitotic arrest followed by apoptosis in 
HCC cells 
Dihydroquinolinones FQI-1 and FQI-2 induce a mitotic arrest in QGY-7703 cells, 
followed in time by apoptosis44,61. Dihydroquinolinone FQI-34 emerged as the lead 
compound from SAR and solubility assays. In particular, antiproliferative activity in QGY-
7703 cells was 467 nM; potent and selective transcriptional inhibition was seen in 
transactivation activities against LSF subfamily members; consistently large thermal shifts 
were observed in CETSAs for LSF and LBP1a/b; and aqueous solubility was greater than 
100 μM. To compare cell cycle consequences, the effect of 1 μM FQI-34 was evaluated in 
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asynchronous QGY-7703 cells after 18 and 42 hours of treatment by propidium iodide (PI) 
staining of the cellular DNA and flow cytometry (FC) quantification. Comparison was 
made to 5 μM FQI-1. At 18 hours, 5 μM FQI-1 showed >55% of cells arrested at G2/M in 
three independent experiments. Similar cell cycle distribution was observed with the 5-fold 
concentration reduction of FQI-34. After an additional 24 hours (42 hours total) each 
compound maintained about 30% of the cell population arrested at G2/M in addition to 
about 45% of cells in sub-G1, indicative of apoptosis (Figure 1.16). 
It was previously shown that synchronized QGY-7703 cells treated with FQIs arrest 
in mitosis with condensed but nonaligned chromosomes – a prometaphase-like state - after 
18 hours and show multinucleated and apoptotic cells by 48 hours61. Morphological 
changes of 1 μM FQI-34 treatment in asynchronous QGY-7703 cells after 18 and 42 hours 
were investigated by immunofluorescence, by staining for actin and DNA. Direct 
comparison was made to 5 μM FQI-1 treatment. Prometaphase is characterized by nuclear 
envelope breakdown and condensed chromosomes that are not aligned as expected in 
metaphase. Chromatin condensation, nuclear shrinking, membrane blebbing, and 
fragmented nuclei are classic characteristics of apoptosis. Cells were analyzed at 60x 
magnification; staining patterns of DNA and actin were consistent with an arrest in a 
prometaphase-like state at 18 hours, followed by multinucleated and fragmented cells at 
42 hours. Representative images are shown in Figure 1.17 and Figure 1.18.  
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Figure 1.16 Dihydroquinolinones induce cell cycle arrest followed by cell death in human HCC cells 
QGY-7703 cells treated with DMSO, 5 μM FQI-1, or 1 μM FQI-34 for the given time points. Cells were 
harvested and DNA was stained with PI and analyzed by flow cytometry. At 18-hours of treatment, cells are 
predominantly arrested at G2/M in both treatment groups. An increase in sub-G1 cell populations and a 
decrease in G2/M populations resulted 24 hours later. Histograms represent cell counts on the y-axis and total 
fluorescence area (FL2-A) on the x-axis. No gates were applied. Histograms are representative of 3 
independent experiments. 
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Figure 1.17 Mitotic defects triggered by dihydroquinolinone treatment after 18 hours 
QGY-7703 cells were treated with indicated inhibitors or DMSO (vehicle control) for 18 hours on poly-L-
lysine (PLL)-coated coverslips. Actin was stained with rhodamine-phalloidin and DNA was stained with 
DAPI. Cells were imaged on an Olympus inverted microscope at 60x magnification. Images are 
representative of the phenotypes observed in the total cell population. Yellow arrows indicate prometaphase 
arrested cells. Scale bar = 20 μm. Representative of two independent experiments.  
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Figure 1.18 Mitotic defects triggered by dihydroquinolinone treatment after 42 hours 
QGY-7703 cells were treated with indicated inhibitors or DMSO (vehicle control) for 42 hours on poly-L-
lysine (PLL)-coated coverslips. Actin was stained with rhodamine-phalloidin and DNA was stained with 
DAPI. Cells were imaged on an Olympus inverted microscope at 60x magnification. Images are 
representative of the phenotypes observed in the total cell population. Pink arrows indicate multinucleated 
cells. Scale bar = 20 μm. Representative of two independent experiments. 
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1.3.5 In life Pharmacokinetic and tolerability studies of FQI-34 
 Pharmacokinetics (PK) is the mathematical study of the movement of xenobiotics 
within the body after their administration. There are four distinct, yet interrelated, 
determinants of PK- absorption, distribution, metabolism, and excretion. These properties 
are commonly referred to as ADME. Absorption describes the process by which 
xenobiotics move from the site of administration to the systemic circulation. The most 
common route of administration is oral ingestion (PO; “per os”). When taken orally, a 
xenobiotic must first get absorbed into the gut and not be susceptible to metabolism by 
intestinal enzymes. It is then delivered to the liver and undergoes first-pass hepatic 
metabolism and/or biliary excretion prior to reaching systemic circulation. Blood flow 
distributes the xenobiotic from the system circulation to the body tissues and organs. The 
xenobiotic may be eliminated in this process by metabolism and/or excretion. When taken 
by intravenous (IV) injection, the xenobiotic bypasses the first-pass metabolism in the liver 
and directly enters systemic circulation and undergoes the processes of distribution, 
metabolism, and excretion. There a number of other routes of administration, however they 
will not be discussed here.62,63    
In-life studies can be extremely useful for determining a compound’s general 
ADME characteristics by means of concentration-vs-time profiles in animal plasma (or 
blood). There are four PK parameters which are the most useful in characterizing the in 
vivo disposition of a compound. These are: 1) clearance (CL, units of volume/time), a 
measure of the body’s ability to eliminate a compound, 2) volume of distribution at steady 
state (VDSS, units of volume), a measure of the apparent volume/space in the body which 
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contains the compound, 3) half-life (t1/2, units of time), a measure of the time it takes for a 
compound to decrease to half of its initial concentration in the plasma (or blood), and 4) 
bioavailability (%F), the fraction of a compound that reaches the systemic circulation 
following PO administration.62 
 The lead compound, FQI-34, was administered to Sprague-Dawley male rats via 
IV and PO administration (3 replicates per administration), at 4 mg/kg and 100 mg/kg doses 
respectively. Plasma samples were collected over a 24-hour period. In-life and 
bioanalytical analyses described here were conducted by Cyprotex (Watertown, MA). 
Collected plasma samples were analyzed with LC/MS/MS to determine FQI-34 
concentrations. Concentration-verse-time profiles were independently generated from 
plasma data (Figure 1.19) and subsequent PK parameters listed in Table 1.7 were 
independently calculated by myself using PKSolver64, a free Microsoft Excel add-in 
program. The derivation of these parameters and their significance in relation to FQI-34 
ADME properties is discussed below.  
Before undertaking in-life studies, the formulation for dosing of FQI-34 had to be 
determined. Volume restrictions exist for animal species and for each route of 
administration65. I wanted a 4 mg/kg IV bolus of FQI-34 for IV administration, because 
this is a therapeutic dose. Rats have an average body weight of 0.25 kg, with dosage 
restrictions of approximately 2.5 mL. This necessitated completely solubilizing FQI-34 at 
0.4 mg/mL (~1.13 mM). After multiple trail-and-error formulations, a 10% Ethanol/16% 
PEG-400/74% saline (0.9% sodium chloride) formulation was chosen for injections. For 
PO administration, 100 mg/kg was the target dose, requiring a 10 mg/mL solution (~28 
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mM). A common formulation for PO dosing is 1% methylcellulose65. Addition of 0.5% 
Tween-80 to the 1% methylcellulose suspension completely solubilized FQI-34 at 10 
mg/mL. 
For both IV and PO dosing, observed average plasma concentrations (ng/mL) of 
FQI-34 were plotted on a natural log scale (ln) versus time to generate the concentration-
time profiles (Figure 1.19; IV in blue, PO in red). Subsequent FQI-34 PK parameters (Table 
1.7) were derived with PKSolver via non-compartment analysis (NCA) using statistical 
moment theory. Non-compartment analysis is a primary PK data analysis method that does 
not require any specific compartmental model for the system and can be applied to nearly 
any PK data without assuming structural or mechanistic properties of the behavior of the 
compound in the body66.  
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Figure 1.19 FQI-34 plasma concentration-time profile in rats 
Average plasma concentration (Cp (ng/mL))-time profiles for FQI-34 administered via intravenous bolus 
(IV) (blue) or orally (PO) (red) to Sprague-Dawley male rats over a 24-hour time period. 
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The peak plasma concentration (Cmax) and the time to reach Cmax (tmax) were directly 
observed from the concentration-time curve. The terminal rate constant (λz) was obtained 
from nonlinear regression analysis of FQI-34 concentration data during the elimination 
phase. The half-life (t1/2) was determined by 0.693/λz.  The area under the plasma 
concentration-time curve (AUC0-t) from time zero to the time of last measured 
concentration (Clast) was calculated by the linear trapezoidal rule. The AUC from time zero 
to infinity (AUC0-) was obtained by the addition of AUC0-t and the extrapolated area 
IV Bolus Dose 4 mg/kg PO Dose 100 mg/kg
Mean Rat 
weight (kg)
0.239
Mean Rat 
weight (kg)
0.247
Cmax (ng/mL) 552 Cmax (ng/mL) 526
tmax (hour) 0.42 tmax (hour) 3
AUC (0-t) 
(ng/mL*h)
919
AUC (0-t) 
(ng/mL*h)
3835
AUC (0-¥) 
(ng/mL*h)
935
AUC (0-¥) 
(ng/mL*h)
4956
CL 
(mL/min/kg)
73
MRT (hour)
7.1
VDSS (L/kg) 5.1 %F 21%
t1/2 (hour) 0.81
MRT (hour) 1.19
Cmax - average peak concentration
tmax - average time of peak concentration
AUC- area under plasma concentration-time curve
CL - average total body clearance
VDSS- average volume of distribution at steady state
MRT- mean residence time 
%F- oral bioavailability
Table 1.7 FQI-34 Rat Pharmacokinetic Paramters
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determined by Clast/λz. The total body clearance (CL) was calculated from the quotient of 
the dose (D) and the AUC0-. The mean residence time (MRT) is the arithmetic mean of 
the duration that a compound resides in the body before being eliminated and can be 
calculated as AUC0-/AUMC0-, where AUMC0- is the area under the first moment curve 
(the AUC of a plot of the product of concentration (Cp) x time (t) versus t). The volume of 
distribution at steady-state (VDSS) is equal to the product of CL and MRT. CL, t1/2, and 
VDSS, are only reported for IV dosing. A radiolabeled (mass balance) type of study would 
be needed for PO dosing to accurately measure clearance. Absorption may be continually 
occurring for the test compound (even during the elimination/terminal clearance phase), 
therefore absolute half-life values also cannot be accurately determined (per conversations 
with Cyprotex). The bioavailability (F) of a compound is the fraction of the PO 
administered dose that reaches the systemic circulation. Absolute bioavailability (%F) is 
determined by calculating the ratio of the dose-normalized AUC0- following PO and IV 
administration.62  
The maximum dose that reaches the plasma (Cmax), an indication of maximum drug 
exposure, was approximately 1.5 μM for each dose and administration. With 
approximately 1.13 mM (IV) and 28 mM (PO) concentration of FQI-34 being dosed, only 
a small quantity of FQI-34 is present in the plasma. This implies that FQI-34 is either 
rapidly eliminated or distributed throughout the tissues/organs. Clearance (CL) is a 
hypothetical volume of plasma that must be “cleared” of compound per unit time to 
produce the observed rate of elimination. FQI-34 clearance was calculated as 73 
mL/kg/min. For a 0.2 kg rat, low clearance is  considered ~12.2 mL/kg/min, medium is 37 
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mL/kg/min, and high is 85 mL/kg/min67. The average body weight for the rats used in the 
IV dosing study was 0.239 kg, therefore FQI-34 had a medium-high clearance rate.  
The volume of distribution at steady state (VDSS) reflects the relationship between 
the amount of FQI-34 in the body tissue versus the blood plasma. Steady state implies rate 
of infusion of a compound is equal to the rate of elimination. VDSS has a physiological 
relevance, although it is not a real physiological volume. A VDSS (L/kg) >1 suggests that 
compound is binding more in tissues than to plasma proteins. The distribution may be 
concentrated in a particular issue/organ or spread throughout the body. A VDSS (L/kg) of 
0.4-1 suggests uniform distribution with similar binding between plasma and tissue. A VDSS 
(L/kg) < 0.4 suggests more binding in the plasma with limited distribution in tissues.66  
VDSS for FQI-34 was found to be 5.1 L/kg. This is extremely high in rats and indicates 
extensive distribution in the tissues/organs.   
CL and VDSS influence the terminal half-life t1/2 (the time it takes for the 
concentration in the plasma to reach 50%). Because of the high CL and VDSS, the half-life 
for FQI-34 was only 0.81 hours (48.6 minutes).   
 The 100 mg/kg orally administered FQI-34 dose had an average bioavailability of 
21%. This was a great improvement over the 0.7% bioavailability of FQI-1 (dosed at 50 
mg/kg in 1% methylcellulose). The bioavailability of a compound reflects the amount of 
drug reaching the general circulation, and depends on the extent of absorption and the rate 
of clearance. Bioavailability is linked to lipid solubility, proper compound formulation, 
susceptibility to gastric acid and digestive enzymes, and the degree of metabolism that 
occurs either in the gut or in the first pass through the liver63.   
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A tolerability study in rats was also performed by Cyprotex. Intravenous dosing of 
FQI-34 in rats at 3 dose levels (5, 15, and 50 mg/kg) was compared to vehicle. A suitable 
formulation had to be found for IV dosing. A 20% DMSO/50% PEG-400/30% saline was 
ultimately chosen after trial-and-error. Six rats were dosed per arm (3 male and 3 female) 
by single IV bolus administration. Rats were monitored over 14 days. Weights, and any 
indications of lethargy, labored breathing, hematuria, and vocalization were documented 
every 2-3 days to evaluate tolerability. All treatments were well-tolerated by the animals 
across the study. Compound treated rats showed a steady weight gain comparable to 
vehicle control rats (Figure 1.20). The “15 mg/kg male Rat B” died upon dosing. This was 
deemed an anomaly from dosing stress and not due to the compound itself. All of the rats 
treated with 50 mg/kg FQI-34 experienced pronation, increased respiratory rate, and 
decreased activity upon dosing. Within 30 minutes every rat returned to normal. All rats 
stayed within normal limits of weight, and showed no indications of lethargy, labored 
breathing, hematuria, and vocalization for the duration of the study. Gross necropsy was 
performed at the end of the study, and no abnormalities were found.  
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Figure 1.20 Average body weight of male and female rats in tolerability study. 
Weights were recorded prior to dosing and compared to 3-, 7, 10-, and 14-days post dose.   
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1.4 MATERIALS AND METHODS 
1.4.1 MTS cell proliferation assay 
QGY-7703 cells were cultured at 37°C in 5% CO2 in DMEM (Dulbecco’s 
modification of Eagle’s Medium; Corning) supplemented with 10% Fetal Bovine Serum 
(FBS; Invitrogen). NIH-3T3 cells were cultured at 37°C in 5% CO2 in DMEM 
supplemented with 10% Fetal Calf Serum (FCS; Atlanta Biologicals). For SAR studies 
1,500 QGY-7703 or NIH-3T3 cells were seeded in 96-well plates for approximately 20 
hours, and then treated with compound or DMSO (vehicle control) at appropriate 
concentrations (DMSO at final concentration of 1%). After a 72-hour incubation with 
compound or vehicle, cell growth was assessed via the Promega CellTiter 96® AQueous 
One Solution Cell Proliferation Assay, a colorimetric method to determine the number of 
viable cells. 20 µL of the CellTiter 96® AQueous One Solution Reagent was added directly 
into cultured wells and incubated for approximately one hour, after which the absorbance 
at 490 nm was read with a 96-well plate reader (Opys MR Microplate Reader). GI50 values 
were determined from plots of the percentage of compound-treated cell growth to vehicle 
cell growth vs. compound concentration (GraphPad Prism; non-linear regression, log 
inhibitor verse normalized response with variable slope). 
1.4.2 Dual luciferase reporter assays 
For dual luciferase reporter assays, NIH-3T3 cells were cultured at 37°C in 5% CO2 
in DMEM (Dulbecco’s modification of Eagle’s Medium; Corning) supplemented with 
10% FCS (FCS; Atlanta Biologicals).  Approximately 24 hours prior to transfection, 
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200,000 cells were plated in 35 mm dishes. After 24 hours, cells were ~70% confluent, and 
were transfected for 5 hours with the reporter construct pGL3B-WT4E1b, phRL-TK, and 
either pEF1α-LSF, pCDNA3-LSF, pCDNA3-LBP1a, pCDNA3-LBP9, or pCDNA3-
GRHL1 with lipofectamine (Thermo Fisher) according to the manufacturer’s protocol. 
Vehicle (DMSO) or dihydroquinolinone compound was then added, keeping DMSO at 
0.5%. Cell extracts were harvested using 1x Passive lysis buffer (Promega Dual-Luciferase 
Reporter Assay System) 40-hours post-transfection and kept at -80⁰C until ready to assay. 
Firefly and renilla luciferase activities were measured via a dual luciferase assay 
(Promega). Relative luciferase activity represents firefly luciferase activity normalized to 
that of renilla luciferase in each extract. IC50 values were determined from plots of 
normalized luciferase activity vs. compound concentration using Prism GraphPad, non-
linear regression 4-parameter curve fit with variable slope.  
1.4.3 Cellular thermal shift assay 
 QGY-7703 cells were cultured as in the MTS assay. Cells were seeded into 10 cm 
plates and allowed to reach 60-80% confluency. After trypsinization (0.05% Trypsin-
EDTA, Invitrogen), the cell pellet was washed twice with ice-cold 1x PBS (137 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.2). The cell pellet was lysed by 
addition of 200 µL freshly prepared ice-cold modified RIPA buffer (50 mM Tris-Cl pH 
7.4, 1% NP-40, 0.1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 10 mM EDTA) 
supplemented with 1 mM Pefabloc (Sigma-Aldrich), and flash frozen in liquid nitrogen 
followed by thawing at room temperature for a total of three cycles. Cell lysate was 
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centrifuged at 20,000 x g for 20 minutes to clarify after third freeze/thaw. Supernatant was 
either treated immediately or saved at -80°C for future use. 200 µL of the lysate was treated 
with dihydroquinolinone (addition of 2 µL 50 mM Stock; 500 µM final in 1% DMSO) or 
vehicle (2 µL DMSO), gently flicked to mix, and incubated for 30 minutes at room 
temperature. For Thio-FQI-1, the lysate was incubated for 30 minutes at 37°C (heat block) 
to observe positive thermal shift. After treatment, the lysate was separated into 20 µL 
aliquots for thermal denaturation. Lysate was heated at the given temperature for 5 minutes, 
then placed on ice for 5 minutes and subsequently centrifuged at 20,000 x g for 10 minutes 
to separate soluble protein from aggregates. 10 µL of the supernatant containing the soluble 
protein was saved at -20°C for immunoblot analysis. Equal amounts of supernatant were 
loaded onto a 10% polyacrylamide gel. Separated proteins were transferred onto 
polyvinylidene difluoride (PVDF) membranes. Membranes were blocked in 5% 
milk/TBST (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% Tween-20), and then probed 
overnight at 4°C with primary antibody (anti-LSF (Millipore; 1:500 dilution in 5% bovine 
serum albumin in TBST), anti-LBP1a/b (Millipore; 1:1000 dilution in 5% bovine serum 
albumin in TBST) or anti-GRHL1 (Sierra Sciences Antibody number B6407; 1:5000 
dilution in bovine serum albumin in TBST)). Secondary goat anti-rabbit HRP-IgG antibody 
(1:3000, 1:3000, and 1:10,000 respectively in blocking buffer) was incubated with 
membranes for 1 hour at room temperature. Protein bands were detected with Immobilon 
Western Chemiluminescent HRP-Substrate (Millipore) and developed on a Kodak RP X-
OMAT Developer. Immunoblots were quantified using Image J and graphed using 
GraphPad PRISM. Area-under-curve (AUC) for the quantified Western blots were 
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calculated with GraphPad PRISM. Non-parametric t-test was calculated to determine 
statistical significance between the curves. Tm50 values were calculated using non-linear 
regression (inhibitor-vs-response, variable slope). 
1.4.4 Kinetic turbidic solubility assay 
Kinetic solubility was measured via a turbidity based assay method in the modified 
RIPA or PBS buffer. 198 µL of 1x RIPA buffer was added to the wells of a 96-well plate. 
For the RIPA buffer analysis, 2 uL 50 mM dihydroquinolinone, freshly dissolved in 
DMSO, was added to the wells and incubated for 30 minutes at room temperature. After 
the incubation period the absorbance at 620 nm was taken on a Spectramax M5 
spectrophotometer.  For PBS buffer, 198 µL of 1x PBS (137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4, 2 mM KH2PO4, pH 7.2) was added to the wells of a 96-well plate. 
Dihydroquinolinone was dissolved in DMSO to a 30 mM final concentration immediately 
before testing. The 30 mM stock was further diluted in DMSO appropriately for the desired 
final concentration to be tested in the solubility assay. 2 µL of these DMSO solutions were 
added to the 96-well plate such that DMSO was kept to 1%. The plate was sealed and 
gently shaken, and allowed to incubate at 37°C for 2 hours, after which the absorbance at 
620 nm was taken. The concentration at which the absorbance was greater than or equal to 
0.01 absorbance units was taken as the precipitation point. For each assay, N = 7. 
1.4.5 Flow cytometry (FC) 
QGY-7703 cells were cultured as above. Approximately 20 hours prior to 
treatment, 2x105 cells were plated in each 60 mm dish. After adhering overnight, FQI-1 
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and FQI-34 stocks in DMSO were added to the cells at the given concentrations and 
incubated for 18 or 42 hours. DMSO was kept at 0.5%. At the given time point, medium 
was collected and put on ice while cell plates were trypsinized. Trypsinized cells were 
combined with the medium and centrifuged at 1000 rpm (Beckman Coulter, Alegra 6R 
centrifuge) for 5 min at 4ºC. Cells were re-suspended in 1 mL ice-cold PBS, centrifuged 
as before and re-suspended in 150 μL ice-cold PBS. The cell suspension was slowly 
pipetted into 350 μL ice-cold ethanol in microfuge tubes to fix the cells (for a final 
concentration of 70% ethanol) and stored at 4ºC until flow cytometry analysis (no longer 
than 2 weeks). On the day of the analysis, fixed cells were centrifuged at 1000 rpm (Thermo 
IEC, Micromax microcentrifuge) for 5 min at 4ºC. Ethanol was gently pipetted off each 
cell pellet, and cells were rinsed with ice cold PBS. PBS was pipetted off the pellet and 
cells were resuspended in 500-1000 μL PI solution (50 µg/mL PI with 10 µg/mL RNaseA 
in PBS), depending on the size of the pellet. Cells were incubated in PI/RNaseA solution 
for 45-60 min in the dark at room temperature. After incubation, the samples were 
transferred to BD Falcon polypropylene round bottom tubes with cell strainer caps and 
placed on ice for FC. FC was performed on a FACSCalibur instrument and >10,000 events 
were collected for each sample. Histograms were generated by plotting the events verse 
the FL2-A channel intensities. The percentages of subpopulations relative to the total cell 
population were computed by marking the ungated histogram peaks with FACSCalibur 
markers (e.g., M1, M2, etc…). Identical subpopulation markers were implemented for each 
treatment and control condition performed in the same run by copying and pasting markers 
between histograms. 
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1.4.6 Immunofluorescence (IF) 
 IF experiments were conducted in parallel to FC experiments. Poly-L-lysine 
coverslips were placed on the bottom of the 60 mm plates. QGY-7703 cells were cultured 
as above. Approximately 20 hours prior to treatment, 2x105 cells were added to the 60 mm 
dishes. After adhering overnight, dihydroquinolinone stocks in DMSO were added to the 
cell plates at the given concentrations and incubated for 18 or 42 hours. DMSO was kept 
to 0.5%. At the given time point, coverslips were transferred to new, empty, 60 mm plates 
and rinsed with PBS. Cells were fixed for 10 min in 3.7% formaldehyde, rinsed with PBS, 
permeabilized in PBS containing 0.1% Triton-X for 10 min, and then rinsed again with 
PBS. Coverslips were then submerged in 1:200 Fluorescein isothiocyanate labeled 
Phalloidin (Sigma) and incubated in the dark for 5 hours at room temperature. Coverslips 
were rinsed twice with PBS, and then tapped dry and mounted with ProLong® Gold 
Antifade Mountant with DAPI (Invitrogen). Samples were imaged on an Olympus AX70 
microscope. 
1.4.7 Pharmacokinetic and tolerability study 
 Studies were conducted at Cyprotex, in Watertown, MA (www.cyprotex.com). The 
following procedure and observations was transferred directly from the Cyprotex study 
report (CYP1441-R1). The study was performed under non-GLP (Good Laboratory 
Practice) conditions. All work was performed with appropriate local health regulation and 
ethical approvals. Plasma samples were taken at 0.08, 0.25, 0.5, 1, 2, 4, 8, and 24 hours 
after dosing. Plasma samples were precipitated with three volumes of methanol containing 
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an analytical internal standard (propranolol/bucetin/diclofenac). Samples were then 
centrifuged to remove precipitated protein, and the supernatant was analyzed by LC-
MS/MS using a Waters Xevo TQ mass spectrometer coupled with an Acuity HPLC and a 
CTC PAL chilled autosampler, all controlled by MassLynx software (Waters). The analyte 
signal was optimized prior to analysis. After separation on a C18 reverse phase HPLC 
column (Waters Acquity HSS T3 2.1x50mm 1.8 μM) using an acetonitrile-water gradient 
system, peaks were analyzed by mass spectrometry (MS) using ESI ionization in multiple 
reaction monitoring (MRM) mode. All plasma samples were compared to a calibration 
curve prepared in rat blank plasma. Male Sprague-Dawley rats were obtained from a 
commercial source and housed in an AAALAC-approved facility until dosing. For IV 
dosing, FQI-34 was dissolved in 10% ethanol/16% PEG-400/74% saline (0.9% NaCl) at 
0.4 mg/mL and in a 1% methylcellulose/0.5% Tween-80 suspension at 10 mg/mL for PO 
dosing. Three rats per group were dosed by a single IV bolus (10 mL/kg) or PO (10 mL/kg). 
The following rodent dosing scheme was used (taken directly from the study report): 
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The concentrations of FQI-34 in the rat plasma samples at each time-point were determined 
to be as follows (taken directly from the study report): 
 
Plasma PK-parameters were independently verified and interpreted by myself using PK-
solver: an Excel add-in64, via a non-compartmental analysis using the linear-trapezoidal 
method. 
 For tolerability studies the FQI-34 was administered by IV at 3 dose levels: 5, 15, 
and 50 mg/kg. FQI-34 was formulated in 20% DMSO/50% PEG-400/30% saline, and 
administered by IV at 5 mL/kg for compound or for vehicle alone. A single dose was 
administered to 6 rats per dose arm were used (3 male and 3 female), with subsequent 
monitoring over 14 days. Weights and observations were taken every 2-3 days. Gross 
necropsy was performed at the end of the study. 
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1.5 CONCLUSIONS 
 The oncogenic transcription factor LSF is a promising molecular target for 
treatment of advanced stage Hepatocellular carcinoma (HCC). Small molecule inhibitors, 
termed Factor Quinolinone Inhibitors (FQIs), are potent antiproliferative agents in HCC 
cells. The dihydroquinolinone compounds showed selective inhibition of the LSF 
subfamily over the closely related Grainyhead subfamily. A strong correlation between 
antiproliferation and cellular transcription inhibition implies cytotoxic effects are a result 
of inhibiting transcriptional activity of the LSF family. A critical measure to determine if 
a drug is specific for a particular pathway is to measure its direct binding to its intended 
molecular target. The cellular thermal shift assay in HCC cell lysates demonstrated for the 
first time direct target binding of FQIs to LSF subfamily members in a cellular context. 
Structure-activity-relationship studies suggest the amide portion of the quinolinone core, 
as well as the substitution pattern of the phenyl ring at the C4 position, are critical for 
activity and largely impact compound solubility.  
Dihydroquinolinone FQI-34 emerged as the lead compound, exhibiting nanomolar 
potency, satisfactory aqueous solubility, and aberrant mitosis in liver cancer cells. It is 
widely recognized that a compound, no matter how active it may be, can never become a 
drug if it does not have appropriate absorption, distribution, metabolism, and excretion 
(ADME) properties. Rat pharmacokinetic and toxicity studies demonstrated that FQI-34 
has passable ADME properties and excellent tolerability. These studies support continued 
advancement of FQI-34 as a HCC drug candidate. 
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CHAPTER TWO 
 
 Effect of dihydroquinolinone FQI-1 on cell proliferation, cell cycle and 
apoptosis in the human leukemia cell line U937  
 
 
2.1 INTRODUCTION 
Chapter one established the oncogenic transcription factor LSF as a druggable 
target for hepatocellular carcinoma therapy. On a clinical level, LSF is overexpressed in 
patient HCC samples. Levels of LSF in HCC patient liver sections correlate to the stage 
and severity of the disease. In mouse models, LSF promotes malignant transformation 
during hepatic oncogenesis. Small molecule dihydroquinolinone compounds, termed FQIs, 
are potent and selective inhibitors of the LSF subfamily of transcription factors. It is 
unknown if LSF, or any of its paralogs, function as an oncogene in other cancers. 
Investigation of FQI antiproliferative activity across a panel of cell lines identified 
hematopoietic cancer lineages as exceptionally sensitive to dihydroquinolinone treatment. 
In the present study, I demonstrate that the dihydroquinolinone FQI-1 induces 
characteristics of apoptosis in U937 human leukemia cells, including DNA fragmentation, 
chromatin condensation, and Annexin V binding. These characteristics are also induced by 
inhibition of LSF and/or LBP1a/b by siRNA knockdown, suggesting sensitivity to FQI-1 
treatment is a result of inhibition of LSF and/or LBP1a/b activity. 
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2.2 BACKGROUND 
2.2.1 Non-HCC tumor cell response to LSF inhibitors 
The dihydroquinolinone inhibitors FQI-1 and FQI-2 were provided to the Harvard-
MIT Broad Institute initiative for the Library of Integrated Network-based Cellular 
Signatures (LINCS). The LINCS program is a multi-institutional research initiative whose 
goal is to better understand how human cells respond to perturbations such as exposure to 
drugs, alterations in the environment, and cellular mutations. The dihydroquinolinones 
FQI-1 and FQI-2 were screened against a panel of 117 cancer cell lines cultured from 
primary sources. Profiling was performed in duplicate in a 384-well plate format. 
Sensitivity to compounds was assessed using the Cell Titer-Glo assay (Promega), which 
measures cellular ATP levels as a representation of cell viability. Sensitivity was 
determined from the area-under-curve (AUC) values for each cell line. Sensitive 
compounds exhibited AUCs < 3.5, whereas AUCs > 5.5 were considered unresponsive. 
Growth curves are shown in Figure 2.1 and the AUC sensitivity values are shown in 
Appendix 3. Treatment with FQI-1 or FQI-2 revealed the same trends (i.e. sensitive or 
unresponsive), with cell lines largely more sensitive to FQI-2 than FQI-1.  
Of the two liver cancer lines tested, one was unresponsive and the other showed 
intermediate sensitivity. The unresponsive cell line HepG2 is less tumorigenic than the 
aggressive QGY-7703 cell line routinely used for dihydroquinolinone testing.  The 
expression status of LSF is unknown in the other cell line, SNU-398.  
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Figure 2.1 LINCS dose response curves. 
A) Cell lines treated with FQI-1. B) Cell lines treated with FQI-2 
Sensitive cell lines (AUC<3.5) are shown in red. Unresponsive cell lines (AUC>5.5) are shown in blue. 
Curves independently supplied by the Broad Institute LINCS data package.  
 
The largest groups of tested cancers were from lung, ovarian, large intestine and 
hematopoietic/lymphoid tissue origins. These collections each contained more than 15 
different representative cell lines. Of the 37 lung cancer and 20 ovarian cancer cell lines 
screened, about half in each group were deemed sensitive and the remaining showed 
intermediate to unresponsive results. The large intestine cell lines were all delineated as 
being colorectal cancers. This group exhibited the second highest sensitivity to FQI-1 and 
FQI-2. About 65% of the colorectal cell lines were sensitive to treatment. Both mRNA and 
protein levels of LSF are overexpressed in colorectal cancer patients68. Histopathology on 
colorectal cancer patient specimens show high levels of LSF correlating to the stage of the 
disease, and a strong correlation between LSF expression and the clinicopathologic 
characteristics of colorectal cancer68. 
Hematopoietic and lymphoid tissue cell lineages demonstrated the most prominent 
65 
 
 
 
response to the antiproliferative effects of the FQI compounds. Of the 117 screened cancer 
cell lines, 18 were of hematopoietic and lymphoid tissue origin. None of the hematopoietic 
cell lines were deemed insensitive to FQI treatment. When treated with FQI-1, 15 had 
AUCs <3.5. When treated with FQI-2, 17 had AUCs <3.5. One of the most sensitive cell 
lines (U937) and an intermediate sensitive cell line (THP-1) were chosen for in-house 
investigation of dihydroquinolinone effects on hematopoietic cells. 
 
2.2.2 U937 and THP-1 Cells 
 The cell lines U937 and THP-1 are commonly used in biomedical research. The 
THP-1 cell line is a human monocytic leukemia cell line derived from the blood of a 1-
year-old male patient with acute monocytic leukemia. THP-1 cells resemble primary 
monocytes in morphology and express distinct monocytic markers.69,70 U937 is a pro-
monocytic human myeloid leukemia cell line isolated from the pleural fluid of a 37 year 
old male with diffuse histiocytic lymphoma. U937 cells resemble blast cells.69,71  
A mouse model has demonstrated that U937 cells are more tumorigenic than THP-
1 cells. In this model, SCID mice were preconditioned by injection with anti-asialo-GM1 
antibody and exposed to sub-lethal total body irradiation at a dose of 3 Gy. Preconditioning 
improves tumor take rate by eliminating natural killer (NK) activity72. Subsequently, mice 
were given an intravenous injection of AML cells. The survival of mice was directly 
correlated with the number of leukemia cells proliferating in vivo. All of the mice showed 
body weight loss, ruffled fur, and paralysis of hind limbs, and then eventually died. 
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Duration to death in the mice engrafted with U937 was more than twice as fast as those 
engrafted with THP-1.73  
A genetic analysis showed that U937 bears the t(10;11)(p13;q14) translocation74. 
This results in a nonrandom fusion between the Ap-3-like clathrin assembly protein CALM 
(Clathrin assembly lymphoid myeloid leukemia) and AF10. AF10, a putative transcription 
factor, is simultaneously a fusion partner of the MLL (myeloid/lymphoid or mixed-lineage 
leukemia) gene74. The translocation is rare, but recurring, and has been observed in acute 
lymphoblastic leukemia as well as acute myeloid leukemia. The t(10;11)(p13;q14) 
translocation is believed to be important for the tumorigenic property of U937 cells75.  
 
2.3 RESULTS AND DISCUSSION 
2.3.1 Antiproliferative effects of FQI-1 on hematopoietic and hepatocellular carcinoma 
cell lines 
 Microarray gene expression data for the cell lines used in the LINCS study is 
publicly available on the Broad Novartis Cancer Cell Line Encyclopedia portal76. 
Comparison of LSF and LBP1a/b mRNA expression in each cell line showed a general 
trend for greater expression of LBP1a/b than of LSF (Figure 2.2). It was previously 
reported that LBP1a is the prevalent family member in mouse primary B lymphocytes, so 
it was not surprising to see greater LBP1a/b levels in the hematopoietic and lymphoid tissue 
lineages77. It was, however, unexpected to see higher levels of LBP1a/b across all cancer 
types.   
mRNA levels for LSF, LBP1a/b, and the sum of the two, were compared to the 
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AUCs for FQI-1 and FQI-2 treatment (Figure 2.3 and 2.4). Neither LSF nor LBP1a/b 
mRNA levels were predictive of cell line sensitivity to dihydroquinolinone treatment.   
 
 
Figure 2.2 LSF and LBP1a/b mRNA expression levels in the LINCS data cell lines 
LSF shown in red, LBP1a/b shown in blue. Cell lines are organized by cell lineage. Gene expression data for 
LSF was extracted from CCLE_Expression_Entrez_2012-10-18.res :Gene-centric RMA-normalized mRNA 
expression data. Gene Expression data for LBP1a/b was extracted from CCLE_Expression_Entrez_2012-10-
18.res :Gene-centric RMA-normalized mRNA expression data. https://portals.broadinstitute.org/ccle/home 
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Figure 2.3 Comparison of LSF, LBP1a/b, and the summation of LSF and LBP1a/b mRNA levels to 
FQI-1 LINCS data AUC values. Red shading indicates sensitive cell lines, with AUC ≤ 3.5, blue shading 
indicates unresponsive cell lines with AUC ≥5.5. No correlation was observed.   
 
 
Figure 2.4 Comparison of LSF, LBP1a/b, and the summation of LSF and LBP1a/b mRNA levels to 
FQI-2 LINCS data AUC values. Red shading indicates sensitive cell lines, with AUC ≤ 3.5, blue shading 
indicates unresponsive cell lines with AUC ≥5.5. No correlation was observed. 
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The activity of the dihydroquinolinone FQI-1 on cell growth was tested in house in 
hematopoietic cell lines U937 and THP-1 by the MTS cell proliferation assay. The potency 
of FQI-1 in the hematopoietic cell lines was compared to those in aggressive and non-
aggressive HCC cell lines as well as immortalized fetal liver hepatocytes. As shown in 
Figure 2.5, results mirrored the LINCS data. U937 cells were confirmed to be very sensitive 
to FQI-1 with a GI50 of 406 nM. THP-1 cells had a GI50 of ~5.5 μM. As mentioned in 
Section 1.3, FQI-1 has a GI50 of 1.3 μM in the aggressive HCC cell line QGY-7703. HepG3 
cells are an HCC cell line which do not form tumors in nude mice28. Both HepG3 and the 
telomerase-immortalized fetal hepatocyte line hTERT-FH-B had a GI50 >20 μM. 
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Figure 2.5. Dose response curves, derived from MTS cell growth inhibition assay, of FQI-1 in sensitive 
and unresponsive Hepatocellular and Hematopoietic cancer cell lines. Error bars represent SD of 
experimental triplicates. 
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The variation in expression levels of LSF and LBP1a/b mRNAs was compared in 
each of the tested cell lines (RT-qPCR performed by Sarah Yunes, Hansen Laboratory; 
data not shown). As concluded with the LINCS microarray data, there was no correlation 
between sensitivity to FQI-1 and mRNA levels of either protein.  
Immunoblot analysis (Figure 2.6) was used to assess relative protein expression of 
LSF and LBP1a/b in the sensitive and unresponsive cell lines. The sensitive QGY-7703 
and U937 cells each showed relatively higher levels of LSF and LBP1a/b proteins. The 
unresponsive hTERT-FH-B fetal hepatocytes showed low levels of both proteins. The 
unresponsive HepG3 liver cancer cells showed low levels of LSF and higher levels of 
LBP1a/b than the immortalized fetal hepatocytes. THP-1 cells showed intermediate 
expression of both proteins. These expression patterns of LSF and LBP1a/b proteins 
correlate moderately to the observed GI50 values. A larger sample set would be needed to 
definitively state that protein levels are indicative of sensitivity thresholds. 
 
Figure 2.6 Relative LSF and LBP1a/b protein levels in FQI sensitive and unresponsive cell lines. 
Representative of two independent experiments. 
71 
 
 
 
2.3.2 Cellular consequences of dihydroquinolinone FQI-1 in U937 cells 
To understand the mechanism underlying the antiproliferative effect of FQI-1 in 
U937 cells, flow cytometry (FC) was used to analyze cell cycle distribution after 18 and 
42 hours of treatment with 1 μM FQI-1 (Figure 2.7). Analysis of the U937 FC data revealed 
that after 18 hours of incubation, FQI-1 induced accumulation of cells either containing a 
G2/M-cellular DNA content or a sub-G1cellular DNA content. By 42 hours, FQI-1-treated 
cells contained a predominant sub-G1 level of cellular DNA, indicative of apoptosis. 
 
 
Figure 2.7 Cell cycle distribution of U937 cells after 1 μM FQI-1 treatment for 18 and 42 hours 
U937 cells treated with DMSO (vehicle control, 42 hours) or 1 μM FQI-1 for the given time points. Cells 
were harvested and DNA was stained with PI and analyzed by flow cytometry. At 18-hours cells are arrested 
in either G2 or M. By 42 hours, the DNA content of the population is predominantly sub-G1, indicative of 
apoptosis. Histograms shown here represent cell counts on the y-axis and total PI fluorescence area (FL2-A) 
on the x-axis. No gates were applied. Histograms are representative of 3 independent experiments. 
 
 
In order to verify the apoptosis phenotype of the cells containing sub-G1 levels of 
DNA, cells were simultaneously assayed for annexin-V staining and propidium iodide (PI) 
uptake. An early event of apoptosis includes translocation of membrane phosphatidylserine 
(PS) from the inner side of the plasma membrane to the surface. Annexin V, a Ca2+-
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dependent phospholipid-binding protein, has high affinity for exposed apoptotic cell 
surface PS. Fluorochrome labeled Annexin V can be used for the detection of PS using FC. 
PS translocation precedes the loss of membrane integrity which accompanies later stages 
of cell death resulting from either apoptotic or necrotic processes. Costaining with PI 
allows identification of early and late apoptotic cells, since viable cells with intact 
membranes exclude PI, whereas the membranes of dead and damaged cells are permeable 
to PI. Thus, cells that are both Annexin V and PI negative are considered viable; cells in 
early apoptosis are Annexin V positive and PI negative; and cells that are in late apoptosis 
or already dead are both Annexin V and PI positive.78  As seen in Figure 2.8, treatment 
with 1 μM FQI-1 for 42 hours induced significant apoptosis, with >60% of the cells positive 
for both markers.  
 
 
 
Figure 2.8 FQI-1 induces severe apoptosis in U937 cells  
U937 cells were labeled with Annexin V and propidium iodide 42 hours after treatment with 1 μM FQI-1. 
FL2-H fluorescence (PI stain) on the y-axis, FL-H fluorescence (Annexin V stain) on the x-axis. Lower left 
quadrant: Viable cells; lower right quadrant: early apoptotic cells; upper right quadrant: Late apoptotic cells; 
upper left quadrant: Non-apoptotic dead cells. Representative data of 2 independent experiments. 
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Morphological changes induced by FQI-1 treatment was assessed by 
immunofluorescence (IF) staining of the DNA and actin. As can be seen in Figure 2.9, the 
nuclear structure of the vehicle control cells remained intact. Chromatin condensation and 
fragmentation were increased in the FQI-1 treated cells. These are characteristics of 
apoptotic cells. These results suggest that the inhibition of cell viability and arrest of the 
cell cycle observed in response to FQI-1 targeting LSF is associated with the induction of 
apoptosis. 
 
 
 
Figure 2.9 Morphological changes induced by 1 μM FQI-1 treatment in U937 cells.  
U937 cells were treated with 1 μM FQI-1 for the indicated time points, or vehicle control (DMSO) for 42 
hours. Cells were fixed, stained with actin for 5 hours and DAPI overnight. Magnification x60. 
Representative of two independent experiments.  
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2.3.3 Cellular phenotypes of siRNA against LSF and LBP1a/b in U937 cells 
 Leukemia cells, and in particular U937 cells, are known to be prone to apoptosis79. 
In order to evaluate the hypothesis that FQI-1 mediated apoptosis in U937 cells was due to 
inhibition of LSF (and/or LBP1a/b), I analyzed phenotypes in U937 cells using RNAi 
technology against LSF, LBP1a/b, and a combination of the two. Jennifer Willoughby 
(Hansen Laboratory) previously described the synthesis and characterization of potent and 
durable siRNAs targeting human LSF and LBP1a/b.  A control siRNA targeting the firefly 
luciferase transcript with a Cy3 fluorescent tag was also synthesized to allow visual 
confirmation of transfection efficiency.61 LSF is a stable protein with half- life of about 
~24 hours80. With 20 nM LSF siRNA, efficient knockdown of protein levels in QGY-7703 
cells was achieved after 72 hours. Treatment of synchronized QGY-7703 cells with LSF 
siRNA, in the presence or absence of LBP1a/b siRNA, resulted in similar phenotypes as 
long-term FQI treatment.61  
In U937 cells, sufficient knockdown of LSF and LBP1a/b protein by these siRNAs 
was not achieved until 168 hours (Figure 2.10). This could be due to poor transfection 
efficiency in the cell type, longer half-life of the proteins in the cell type, or because U937 
cells express more LSF and LBP1a/b protein than do QGY-7703 cells. Comparison of the 
fluorescence signal upon co-transfection of Cy3 tagged siRNA with LSF and/or LBP1a/b 
siRNAs revealed efficient uptake (data not shown). This implies that protein abundance 
and/or stability contributes to the prolonged signal in these cells. 
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Figure 2.10 Efficient knockdown of LSF and LBP1a/b protein levels in U937 cells achieved after 168 
hours 
Lipid transfection of U937 cells with 20 nM siRNA targeting either LSF alone, LBP1a/b alone, or upon 
cotransfection of either with a Cy3-labeled luciferase control. Efficient knockdown is reached after 168 
post transfection. Representative of single experiment.  
 
 
Cell cycle phenotypes of the cells upon knockdown of these proteins was analyzed 
using flow cytometric analysis of PI-stained cellular DNA, 120, 144, and 168 hours after 
transfection of the cells with 20 nM siRNA against either LSF, LBP1a/b, or both (Figure 
2.11). At 120 and even 144 hours, cells remained relatively normally distributed throughout 
the cell cycle. By 168 hours cells appeared to arrest in S phase, coinciding with the 
emergence of a sub-G1 peak in LSF and LBP1a/b siRNA treated cells but not in the control 
cells. This suggested that cells were undergoing apoptosis. In order to analyze this 
possibility, non-permeabilized cells were stained with Annexin-V and PI after treatment 
with siRNAs (Figure 2.12). By 168 hours, siRNA treated cells showed a marked increase 
in late-apoptotic cells (>20%). This was similar to the FQI-1 treated cells, albeit not as 
severe. Morphological changes upon siRNA treatment were identical to those induced by 
FQI-1. As can be seen in Figure 2.13, cells were observed with chromatin condensation, 
fragmented nuclei, and formation of apoptotic bodies.  
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Figure 2.11 Cell cycle distribution of U937 cells following siRNA treatment 
Lipid transfection of U937 cells with 20 nM siRNA against LSF, LBP1a/b, or both, -or a Cy3-siRNA against 
luciferase as a negative control. Cells were harvested at the given time points and DNA was stained with PI 
and analyzed with flow cytometry. By 168 hours, the cell populations treated with LSF and LBP1a/b siRNAs 
are predominantly in S phase. Histograms shown here represent cell counts on the y-axis and total 
fluorescence area (FL2-A) on the x-axis. No gates were applied. Histograms are representative of 2 
independent experiments. 
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Figure 2.12 Lipid siRNA transfection induces apoptosis in U937 cells 
U937 cells were labeled with Annexin V and propidium iodide at the given time points after treatment with 
1% DMSO as negative control, siRNA against LSF, LBP1a/b, or both. FL2-H fluorescence (PI stain) is 
indicated on the y-axis, and FL1-H fluorescence (Annexin V stain) is on the x-axis. These data are 
representative of 2 independent sets of experiments. Lower left quadrant: Viable cells; lower right quadrant: 
early apoptotic cells; upper right quadrant: Late apoptotic cells; upper left quadrant: Dead cells. 
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Figure 2.13.  Morphological changes induced by siRNA knockdown in U937 cells after 168 hours  
Lipid transfection of U937 cells with siRNA targeting LSF, LBP1a/b, both, or an Cy3-labeled control, for 
168 hours. Cells were fixed, stained to visualize actin for 5 hours and with DAPI overnight. Magnification 
x60. Images are representative of the phenotypes observed in the total cell population. Yellow arrows indicate 
apoptotic cells. Scale bar = 20 μm. Representative of two independent experiments. 
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The phenotypes resulting from siRNA treatment targeting LSF, LBP1a/b, or both, 
did not completely coincide with those from FQI-1 treatment. Prolonged siRNA treatment 
leads to an S phase arrest with induction of apoptosis, whereas FQI-1 treatment leads to a 
G2/M arrest followed in time by extensive apoptosis. It has previously been shown that 
inhibition of LSF with a DNA binding mutant (dominant-negative LSF, dnLSF) induces 
apoptosis during S phase in growth stimulated NIH-3T3 mouse fibroblast cells and human 
prostate cancer cells. This induction of apoptosis can be rescued by the addition of low 
concentrations of thymidine.33 Treatment of QGY-7703 cells with FQI-1 has been shown 
to act independently of this mechanism41. In the future, it would be valuable to determine 
whether thymidine also relieves the siRNA treated cells from S phase arrest.  
An alternative biological basis for the discrepancy between phenotypes derived 
from siRNA and small molecule inhibition is typically attributed to protein-protein 
interactions (PPI)81. A protein treated with a small-molecule inhibitor may still act as a 
scaffold for PPIs, whereas these would be disrupted by siRNA treatment. The Hansen 
laboratory has shown that FQI inhibition of LSF has both transcriptional effects through 
inhibition of DNA binding, and also non-transcriptional effects suggested to be due to 
disruption of PPIs (data not shown)61.  It is possible LSF and/or LBP1a/b are involved in 
many PPI unaffected by FQI-1 treatment leading to discrepancies in siRNA and FQI-1 
inhibition of LSF family proteins. 
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2.4 MATERIALS AND METHODS 
2.4.1 MTS cell proliferation assay 
U937 and THP-1 cells were cultured at 37°C in 5% CO2 in RPMI-1640 (Invitrogen) 
supplemented with 10% Fetal Bovine Serum (FBS; Invitrogen). QGY-7703, HepG3, and 
hTERT-FH-B cells were cultured at 37°C in 5% CO2 in DMEM (Dulbecco’s modification 
of Eagle’s Medium; Corning) supplemented with 10% FBS (Invitrogen). For U937 and 
THP-1 suspension cells, 2,500 cells were added to the wells of a 96-well plate on the day 
of treatment. For adherent cells, 1,500 QGY-7703 or HepG3, and 2,500 hTERT-FH-B cells 
were seeded in 96-well plates for approximately 20 hours prior to treatment. Cells were 
treated with compound or DMSO (vehicle control) at appropriate concentrations (DMSO 
at final concentration of 1%). After 72-hour incubation with compound or vehicle, cell 
growth was assessed via the Promega CellTiter 96® AQueous One Solution Cell 
Proliferation Assay, a colorimetric method to determine the number of viable cells. 20 µL 
of the CellTiter 96® AQueous One Solution Reagent was added directly into cultured wells 
and incubated for approximately one hour for adherent cells and approximately three hours 
for suspension cells. The absorbance at 490 nm was read with a 96-well plate reader (Opys 
MR Microplate Reader). GI50 values were determined from plots of the percentage of 
compound-treated cell growth to vehicle cell growth vs. compound concentration 
(GraphPad Prism; non-linear regression, log inhibitor verse normalized response with 
variable slope). 
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2.4.2 Immunoblot analysis 
 For adherent cells, a ~80% confluent 10 cm plate was placed on ice and cells were 
scraped into 200 μL ice-cold PBS buffer and transferred into a pre-cooled microfuge tube. 
Suspension cells were spun down at 1,000 rpm (Beckman Coulter, Alegra 6R centrifuge), 
for 5 minutes at 4°C and resuspended into 200 μL ice-cold PBS buffer. At this time cells 
were counted. Following cell count, cells were spun down at 1,000 rpm at 4°C. Cell pellets 
were dissolved directly in 1x Laemmli SDS-PAGE buffer (0.1% 2-Mercaptoethanol, 
0.0005% Bromophenol blue, 10% Glycerol, 2% SDS, 63 mM Tris-HCl pH 6.8) at 1x106 
cells/mL. Equal amounts of cell suspension were loaded onto a 10% polyacrylamide gel. 
Separated proteins were transferred onto polyvinylidene difluoride (PVDF) membranes. 
Membranes were blocked in 5% milk/TBST (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% 
Tween-20), and then probed overnight at 4°C with primary antibody (anti-LSF (Millipore; 
1:500 dilution in 5% bovine serum albumin in TBST), anti-LBP1a/b (Millipore; 1:1000 
dilution in 5% bovine serum albumin in TBST). Secondary goat anti-rabbit HRP-IgG 
antibody (1:3000 in blocking buffer) was incubated with membranes for 1 hour at room 
temperature. Protein bands were detected with Immobilon Western Chemiluminescent 
HRP-Substrate (Millipore) and developed on a Kodak RP X-OMAT Developer. 
2.4.5 Flow Cytometry (FC) 
Cells were cultured as above. On the day of treatment, 10,000 cells were suspended 
in T-25 flasks, and treated with FQI-1 or siRNA at the given concentrations. DMSO was 
kept at 0.5%. At the given time point, cells and medium were collected and centrifuged at 
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1000 rpm (Beckman Coulter, Alegra 6R centrifuge), for 5 min at 4ºC. Cells were re-
suspended in 1 mL ice-cold PBS, and then centrifuged and re-suspended in 150 μL cold 
PBS. The cell suspension was slowly pipetted into 350 μL cold ethanol in microfuge tubes 
to fix cells (70% ethanol) and stored at 4ºC until flow cytometry analysis (no longer than 
2 weeks). On the day of the analysis, fixed cells were centrifuged at 1000 rpm (Thermo 
IEC, Micromax microcentrifuge), for 5 min at 4ºC. Ethanol was gently pipetted from the 
cell pellet, and cells were rinsed with ice cold PBS. PBS was pipetted from the cell pellet 
and cells were resuspended in 500-1000 μL PI solution (50 µg/mL PI with 10 µg/mL 
RNaseA in PBS), depending on the size of the pellet. Cells were incubated in PI/RNaseA 
solution for 45-60 min in the dark at room temperature. After incubation, the samples were 
transferred to BD Falcon polypropylene round bottom tubes with cell strainer caps and 
placed on ice for FC. FC was performed on a FACSCalibur instrument and 10,000 events 
were collected for each sample. Histograms were generated by plotting the number of 
events versus the FL2-A channel intensities. The percentages of subpopulations relative to 
the total cell population were computed by marking the ungated histogram peaks with 
FACSCalibur markers (e.g., M1, M2, etc…). Identical subpopulation markers were 
implemented for each treatment and control condition performed in the same run by 
copying and pasting markers between histograms. 
2.4.6 Annexin V Staining 
Cells were cultured and treated as above. Annexin V and PI staining were 
conducted using BD Pharmingen FITC Annexin V Apoptosis Detection Kit I. According 
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to the manufacturer’s protocol, on the day of the experiment cells and media were harvested 
by centrifugation at 1000 rpm (Beckman Coulter, Alegra 6R centrifuge) for 5 min at 4ºC. 
The supernatant was discarded and the cells were washed twice with ice cold PBS and then 
resuspended in 1x Binding buffer at a concentration of 1x106 cells/mL. 100 μL of the 
solution (1x105 cells) was transferred to a 5 mL culture tube. 5 μL of FITC Annexin V 
solution and 5 μL of PI solution was added to each of the treatment groups. Controls 
included unstained cells, cells stained with only 5 μL of FITC Annexin V solution, and 
cells stained with only 5 μL of PI solution. Cells were gently vortexed and incubated for 
15 min at room temperature in the dark. After 15 minutes, 400 μL 1x Binding buffer was 
added to each tube and the samples were analyzed by FC within 1 hour on a FACSCalibur 
instrument. 10,000 events were collected for each sample. Scatter plots were generated by 
plotting the FL2-H fluorescence (PI stain) on the y-axis and FL-H fluorescence (FITC 
Annexin V) on the x-axis. The negative control (unstained, untreated cells) was used to 
bring the population of cells into the first quadrant of the scatter plot. Compensation was 
used to adjust the signals from the FITC Annexin V-only stained untreated cells to the 
lower right quadrant, and the PI-only stained untreated cells to the upper left quadrant. 
Once instrument settings were achieved, treated samples were analyzed using the saved 
instrument setting and compensation. 
2.4.7 Immunofluorescence (IF) 
IF experiments were conducted in parallel to FC experiments. After the indicated 
treatment time, 250 μL of cell suspension was transferred to microfuge tube, and washed 
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with 1x ice cold PBS. Cells were fixed for 10 min in 200 μL 3.7% formaldehyde and gently 
pipetted onto poly-L-lysine cover slips. Cover slips were spun down at 3000 rpm (Beckman 
Coulter, Alegra 6R centrifuge), room temperature for 5 minutes. After spinning down, 
majority of the cells were adhered to the cover slip. Cells were rinsed with PBS, and then 
permeabilized in PBS containing 0.1% Triton-X for 10 min, and then rinsed again with 
PBS. Coverslips were then submerged in 1:200 Fluorescein isothiocyanate labeled 
Phalloidin (Sigma) and incubated in the dark for 5 hours at room temperature. Coverslips 
were rinsed twice with PBS, and then tapped dry and mounted with with ProLong® Gold 
Antifade Mountant with DAPI (Invitrogen). Samples were imaged on an Olympus AX70 
microscope. 
2.4.8 siRNA transfection 
 Reverse lipid siRNA transfection was performed with Lipofectamine® RNAiMAX  
(Invitrogen) following the manufacturer’s protocol. For a single experiment, 12 pmol of 
RNAi duplex was diluted in 200 µl Opti-MEM® I Medium without serum in an Eppendorf 
tube and mixed gently. Lipofectamine® RNAiMAX was gently mixed before use, and 3 
µl was added to the diluted RNAi molecules. The solution was mixed gently and incubated 
for ~20 minutes at room temperature. U937 cells were cultured as above. For transfection, 
cells were diluted in complete growth medium without antibiotics so that 1 mL contained 
20,000 cells. After the 20 min incubation period, 200 μL of the diluted RNAi 
molecules/lipofectamine solution was added to a single well in a 6-well plate. 1 mL of the 
diluted cells was then added to give a final volume of 1.2 mL and a final RNA concentration 
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of 20 nM. The plate was gently mixed by rocking back and forth and placed in the incubator 
for the given time points.  
  
86 
 
 
 
2.5 CONCLUSIONS 
 Inhibition of the oncogenic transcription factor LSF by factor quinolinone 
inhibitors (FQIs) was shown to affect different cancer types. Most prominently, FQIs have 
previously been shown to inhibit hepatocarcinogenesis in Hepatocellular carcinoma (HCC) 
mouse models wherein LSF functions as an oncogene. In this work, FQIs were screened 
against a panel of 117 different human cancer cell lines. Hematopoietic and lymphoid 
tissue cell lines emerged as particularly sensitive to growth inhibition. Sensitivity values 
were greater than those seen in aggressive HCC cell lines. Comparison of mRNA levels of 
both LSF and its closely related family member LBP1a/b failed to show any correlation to 
sensitivity to FQI treatment. In a small subset of cell lines of sensitive and unresponsive 
HCC and hematopoietic lineages, there was an apparent correlation of sensitivity to LSF 
and LBP1a/b protein levels. Analysis across several cell lines would need to be made to 
conclusively determine if protein levels are predictive of FQI sensitivity. 
In a proof-of-concept analysis, the human leukemic cell line U937 was used to 
investigate the effects of FQI-1 on a nanomolar sensitive hematopoietic cell line. Analysis 
of the cell cycle progression revealed a mitotic arrest followed in time by dramatic 
induction of apoptosis. Morphologically, FQI-1 treated cells showed extensive 
fragmentation of nuclei, symptomatic of apoptosis. Treatment of U937 cells with siRNA 
against LSF and LBP1a/b revealed similar morphological phenotypes to those from FQI-1 
treatment. Fragmented nuclei and induction of apoptosis was seen after siRNA knockdown 
of both proteins.  Cell cycle distribution revealed induction of apoptosis as well as an S 
phase arrest. Further studies are needed to clarify the mechanism by which LSF and 
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LBP1a/b are involved in the development and progression of hematopoietic carcinogenesis 
and whether LSF and/or LBP1a/b function as oncogenes in this cancer type.  
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CHAPTER THREE 
 
Characterization of recombinant LSF protein 
 
3.1 INTRODUCTION 
Chapters one and two described the development of a family of small molecule 
inhibitors that directly target the oncogene LSF in a cellular setting. On a structural level 
LSF protein is only partially understood. Deletion and mutational analysis in concert with 
computational fold recognition and structure prediction models have delineated two core 
domains. The N-terminus encompasses the DNA binding domain whereas the C-terminus 
encodes oligomerization domain(s). This chapter describes challenges encountered with 
recombinant purification of His-tagged LSF protein and LSF protein domains. A truncated 
LSF protein is proposed to adopt a molten-globule like state, which is inherently flexible 
allowing for interaction with DNA and a wide protein network. 
 
3.2 BACKGROUND 
3.2.1 Structure/function analysis of Late SV40 Factor 
 Transcription factors generally have a modular structure encompassing a sequence 
specific DNA-binding domain (DBD) and a separate transactivation and/or transrepression 
domain responsible for causing stimulatory or inhibitory effects through interaction with 
multiple cofactors (coactivators/corepressors)82. Many TFs also possess an oligomerization 
domain and form homo- or hetero-oligomers in order to function properly82. Human LSF 
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is a 502‑amino acid protein with a molecular weight of ~57 kDa. Protein structure 
prediction and fold recognition software, combined with previous mutational analyses27,  
have elucidated the domain barriers and structure-to-function relationship of the LSF 
protein. These predictions often coincided with data from external mutational and 
biochemical assays. 
Transcriptional activation domains have been mapped to amino acids 1-65 and 164-
277. Residues 266-306 are necessary and sufficient for transcriptional repression.26,27 
Secondary structure prediction and sequence conservation comparing LSF and GRH 
families identified two distinct modules, whose functions had previously been identified49: 
an N-terminal DNA-binding region and a C-terminal oligomerization region83. Protein 
structure prediction analysis predicted residues 65-259 encompass the DBD and adopt a 
similar fold to the p53/p63/p73 family of TFs, despite having only ~13% amino acid 
sequence similarity83. The p53/p63/p73 family adopts a consistent immunoglobin-like fold 
(Ig-fold) in binding to DNA83,84. Immunoglobulin-like folds have been found in several 
TFs and are characterized by a β-sandwich of seven or more strands in two sheets that use 
loops as the primary structural element for DNA contact84. In addition to making DNA 
contacts, Ig-folds have been shown to mediate homo- and hetero-dimerization interactions. 
The side chains involved in dimerization lie along one side of the β sandwich, leaving loops 
free to contact the DNA.84 Biochemically, in vitro assays show the LSF DBD also 
apparently contains an LSF-LSF interaction region, although not the predominant LSF-
LSF oligomerization sequences49. A splice variant of LSF, termed LSF-ID, has an internal 
deletion within the DBD (residues 189-239) which does not bind LSF DNA binding sites 
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or dimerize with full length LSF.85 In vitro analysis of LSF truncation mutants indicate the 
minimal region required for DNA binding activity (at 4°C) is amino acids 64-38349. This 
includes not only the DBD but also a portion of the oligomerization region. As mentioned 
in section 1.3.2, LSF is a dimer in solution and binds DNA as an obligate tetramer. Residues 
326-502 comprise the C-terminal oligomerization region. C-terminal deletions mapped two 
sets of oligomerization domains, amino acids 377-403 and 403-50249. Computationally, 
residues 326-388 are predicted to adopt a sterile-alpha-motif (SAM)83. Sterile alpha motifs 
are found in a large number of diverse proteins and are known to be involved in protein-
protein interactions via either homo- or hetero-oligomerization86. The SAM domain is 
found in all LSF subfamily members, but not in the GRH subfamily. The SAM domain is 
inferred to be involved in LSF tetramerization48,80. Residues 386-502 are predicted to adopt 
an ubiquitin-like fold of a β-grasp (ββαββ topology). The ubiquitin-like fold (UB) predicted 
in LSF has been known to be involved in dimerization and it’s assumed the UB promotes 
stable LSF dimerization.48,80,83 A schematic of LSF topology is shown in Figure 3.1. 
 
 
Figure 3.1 Structural/functional regions of LSF  
Schematic of LSF topology. Not drawn to scale. The N-terminal domain is responsible for DNA binding, 
while the C-terminal domain is responsible for oligomerization. The region containing the DNA binding 
domain (DBD) is shaded in pink. The sterile alpha motife (SAM domain is shaded in orange and the 
ubiquitin-like domain (UB) is shaded in yellow. The activation and repression domains are indicated by bars.  
DBD
65-259
UB
384-502
SAM
326-385
activation
1-65
activation
164-277
repression
266-396
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3.2.2 Functional disorder in transcription factors 
The classic structure-function paradigm maintains that a well-defined three-
dimensional (3D) protein structure is a prerequisite for protein function. However, it is now 
recognized that the functional state for many proteins and protein domains are intrinsically 
disordered. Intrinsically disordered proteins (IDP) lack a single, stable conformation in 
their native functional state. IDPs exist as dynamic ensembles with no well-defined 3D 
structure.87,88 Proteins have been found to be entirely disordered or contain both structured 
regions and disordered regions (IDR; intrinsically disordered region)87,88. Some IDRs 
contain sequence elements that interact with partners and frequently fold upon binding, 
others serve as flexible linkers or loops between interaction domains88. Most proteins are 
neither fully ordered nor fully disordered, but are proposed to function within a 
conformational continuum. The spectrum ranges from tightly folded single domains with 
little to no disorder, multidomain proteins that may or may not have a flexible linker IDR, 
compact but disordered molten globules, and finally to highly extended, heterogeneous 
unstructured coils88,89. Tightly folded globular proteins adopt 3D folds stabilized by 
noncovalent interactions such as hydrogen bonds, hydrophobic forces, and van der Waal’s 
interactions. Compact molten globules are characterized by lack of a stable 3D structure 
however they possess well-developed secondary structural elements in folding patterns 
close to that of ordered globular proteins.90 Pre- or “collapsed”- molten globules have less 
pronounced secondary structure than compacted molten globules, representing a 
“squeezed” and partially ordered form of a coil90. True random coils are rare, especially in 
non-denaturing media, and the most extensive IDPs show a propensity to form local 
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elements of secondary structure or hydrophobic clusters.  
Intrinsically disordered proteins are characterized by a bias in sequence 
composition, with a low content of bulky hydrophobic and aromatic amino acids which 
normally form the core of a folded globular protein (Val, Leu, Ile, Met, Phe, Trp and Tyr), 
and a high content of charged and polar amino acids (Gln, Ser, Pro, Glu, Lys, Gly and 
Ala)88. Low complexity sequences with over-representation of a few residues are also 
hallmarks of IDPs and IDRs. Linker sequences between IDRs vary greatly in length and 
composition.88 A number of computer programs have been developed for the prediction of 
protein disorder on the basis of sequence analysis. Different types of protein disorder exist, 
differing in the extent (i.e., the amount of residual secondary and/or tertiary structure) and 
length of disorder. Predictors rely on different physicochemical parameters, and may or 
may not have been trained on data sets of disordered proteins. Some predictors perform 
better on short disordered regions within globally ordered proteins while others perform 
better on long disordered segments.91  
Intrinsically disordered proteins are enriched in proteins that have a role in the 
regulation of signaling pathways and essential cellular processes including transcription, 
chromatin remodeling functions, and regulation of the cell cycle and mitosis (Table 3.1)92. 
Many TFs have been shown to be IDPs, and their inherent flexibility plays a crucial role in 
the affinity and specificity to DNA recognizing processes93. The tumor suppressor p53 is 
a classic example of a TF containing large, unstructured regions in its native state94. The 
topology of p53 can be divided into three functional regions: 1) an N-terminal domain 
(residues 1-93) containing an acidic transcriptional activation domain and a proline-rich 
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domain; 2) a core DBD (residues 102-292); and 3) a C-terminal tetramerization domain 
(residues 320-356) and a regulatory domain (residues 363-393). Similarly to LSF, p53 
binds to its cognate DNA sequence as a tetramer. Mutational analysis of the stability of 
p53 fragments revealed that full-length p53 contains large unstructured coils and loops, 
accounting for about two-thirds of the protein, whereas the DBD and tetramerization 
domains are stably folded.94 Prediction of p53 disorder on the basis of amino acid sequence 
correlates to the mutational analysis, and can be mapped to structures of p53 domains 
bound to different partners confirmed in the Protein Data Bank (PDB)88. The DBD and the 
tetramerization domain align remarkably well with the predicted regions of protein order, 
whereas both the N- and C-terminal regions are predicted to be largely unstructured85. 
Upon binding to partner proteins, p53 undergoes disorder-to-order transitions. The N-
Table 3.1 Correlation of structural disorder 
with Swiss-Prot functional Categories. LSF 
functions bolded. Adopted from Ref 93
Top functions that correlate with long disorder
Meiosis
Protein transport
Apoptosis
Mitosis
mRNA splicing
mRNA processing
Cell cycle
DNA condensation
Spermatogenesis
Transcription regulation
Transcription
Differentiation
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terminus undergoes a transition from a disordered to an α-helical state upon interaction 
with partner proteins, a hallmark being Mdm285. The flexible C-terminal region also 
interacts with multiple partners, giving rise to different tertiary structures when bound to 
different partner proteins88. The interfaces of IDPs are suited for small-molecule 
interference, because they usually bind their partner through recognition motifs in a way 
resembling the binding of substrates to the active sites of enzymes92. This strategy has 
proven successful with Nutlin analogs. Nutlin analogs are potent and selective small 
molecule inhibitors of the Mdm2 interaction sequence that binds p53, and have made their 
way into the clinic95. 
 
3.3 RESULTS AND DISCUSSION 
3.3.1 Cloning and purification of recombinant His-tagged LSF domains 
Late SV40 Factor is composed of the two domains outlined in section 3.2. The 
objective of the current study was to purify recombinant LSF protein domains in sufficient 
yields for use in biochemical characterization, inhibitor studies, and crystallization trials. 
A total of six LSF constructs were cloned for protein expression. 1) FL-LSF: Full length 
LSF, complete protein. 2) Δ65-LSF, this construct is missing the first transactivation 
domain (amino acids 1-65). 3) DBD-LSF, this construct comprises the predicted DBD 
amino acids 65-259. 4) SAM-LSF, this construct encompasses the predicted SAM 
tetramerization domain, amino acids 326-388. 5) UB-LSF, the predicted ubiquitin-like 
fold, residues 384-502. 6) The complete C-terminal oligomerization domain, a SAMUB-
LSF fusion construct consisting of residues 326-502.  
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The LSF constructs were cloned into a pET15b-TEV parent expression plasmid 
(provided by Dr. Karen Allen, Boston University). The plasmid contains a pET15b 
backbone encoding an N-terminal hexahistidine (His6) tag followed by a tobacco etch virus 
(TEV) protease cleavage site (ENLYFQG). All constructs were confirmed by DNA 
sequencing (Eurofin). Purified construct plasmids were transformed into chemically 
competent E. coli strain BL21 (DE3) cells and grown on antibiotic selection plates. BL21 
(DE3) cells contain the T7 expression system and are suitable for isopropyl β-D-1-
thiogalactopyranoside (IPTG) induction of expression. Initial small scale (10 mL) 
expression screens surveyed IPTG concentration, induction temperature, and induction 
time for optimal expression conditions. These screens indicated 0.3 mM IPTG at 16°C for 
18 hours was the optimal condition for protein construct expression. 
Constructs were expressed on a 2-liter scale and purified under native conditions 
according to standard nickel-affinity column protocols. 10 mM imidazole was added to 
bacterial lysates before passing over His-Select Nickel affinity resin (Sigma) to minimize 
non-specific protein binding. The column was washed with a 10 mM imidazole buffer at 
pH 8.0 followed by a 20 mM imidazole buffer at pH 8.0 until the absorbance at 280 nm 
was ~0. Proteins were eluted from the column with a 250 mM imidazole buffer at pH 8, 
and exchanged into an imidazole free buffer (see Materials and Methods for more details). 
The His6-TEV tag was retained on all constructs. Each protein was readily expressed with 
IPTG. Downstream purification steps showed varying purification difficulties for the 
different constructs. The full length LSF and SAMUB-LSF constructs are speculated to 
have formed inclusion bodies. Each showed induction with IPTG yet were absent in the 
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lysis supernatant (Figure 3.2). All constructs were lysed by incubation with an ice cold 
lysozyme solution followed by sonication to manually disrupt the cell pellet. Both the 
SAM-LSF and the UB-LSF constructs were not pure when eluted from the nickel affinity 
column under native conditions (Figure 3.2). Only the Δ65-LSF and DBD-LSF constructs 
were reproducibly purified in suitable yields for downstream assays (~8 and ~10 mgs per 
2 L culture respectively) with purity >95% (Figure 3.2).  
Greater than 95% purity of DBD-LSF, SAM-LSF, and UB-LSF constructs was 
achieved under denaturing conditions (Figure 3.3; see Materials and Methods for 
conditions). Each of the denatured proteins precipitated out of solution upon buffer 
exchange, however. All attempts to refold or solubilize the constructs by dialysis into 
different buffers ranging from pH 3-9 failed.   
 Dynamic light scattering (DLS) was used to assess the aggregation state and 
measure the polydispersity (%PD) of the purified proteins. In this method, a microcuvet of 
protein solution is illuminated by laser light. Brownian motion of the protein molecules 
causes fluctuations in the scattered light intensity, which is measured by a detector placed 
at a 90° angle to the incident laser light. Large particles move slower than small particles. 
The velocity of the Brownian motion is defined by a translational diffusion coefficient DT, 
derived from an autocorrelation function. The apparent size of the particles, the 
hydrodynamic radius (RH), is calculated from DT. The primary DLS measurements are 
RH, and %PD. A monodisperse protein sample has a PD of less than 20%.96 At 
concentrations ranging from 0.5 – 10 mg/mL, the DBD consistently showed >20% PD, 
with RH >10 nm. This indicated the protein sample was largely aggregated into high-order 
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oligomers (Figure 3.4). The Δ65-LSF protein construct showed PD > 20% at 
concentrations larger than 2.5 mg/mL. At concentrations less than 2.5 mg/mL, Δ65-LSF 
was monodisperse with %PD ranging from 0-15% and RH < 10 nm (Figure 3.4). The Δ65-
LSF protein construct consistently provided pure, homogenous protein, and was used for 
further characterization. 
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Figure 3.2 Native purification of His6 tagged LSF domains 
LSF protein domains were expressed from 2 L of induction culture and purified with His-Select Ni-affinity 
resin. Representative SDS-PAGE gels. Lane1: Protein molecular weight ladder. Lane 2: Un-induced culture. 
Lane 3: Induced culture. Lane 4: Lysis supernatant. Lane 5: Column flow through. Lane 6: 20 mM Imidazole 
Wash. Lane 7: Elution. Full length LSF protein (MW 59 kDa) and SAMUB-LSF (MW 22 kDa) were present 
in the induction lane but absent from lysis supernatant. The SAM-LSF construct (MW 9 kDa) and UB-LSF 
construct (16 kDa) reproducibly were eluted from the column as impure proteins. The Δ65-LSF (MW 52 
kDa) and DBD-LSF construct (MW 25 kDa) routinely were eluted from the column at >90% purity. 
  
99 
 
 
 
 
 
Figure 3.3 Purification of His6-tagged LSF domains under denaturing conditions 
LSF protein domains were expressed from 2 L of induction culture and purified with Ni-NTA affinity resin 
under denaturing conditions. Representative SDS-PAGE gels. Lane1: Protein molecular weight ladder. Lane 
2: Induced culture. Lane 3: Lysis supernatant. Lane 4: pH 6.3 Wash #1. Lane 5: pH 6.3 wash #2. Lane 6: pH 
4.5 wash buffer (elution). Lane 7: Empty. Lane 8: Dialyzed sample (pH 7.4). The oligomerization domain 
(SAMUB-LSF; MW 22 kDa) eluted from the column impure. The sterile alpha motif (SAM-LSF; MW 9 
kDa) and Ubiquitin-like fold (UB-LSF; 16 kDa) and DNA-binding domain (DBD-LSF; MW 25 kDa) eluted 
from the column at >90% purity. 
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Figure 3.4 Representative dynamic light scattering spectra for Δ65-LSF and DBD domains 
Top: Δ65-LSF. At concentrations ≤ 2.5 mg/mL, Δ65-LSF is a monomodal, homogenous solution, whereas 
at greater concentrations it forms aggregates. Bottom: DBD-LSF. The DNA-binding domain (DBD) forms 
aggregates at both high and low concentrations tested.  
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3.3.2 Recombinant His6-Δ65-LSF is characteristic of a molten globule 
 An EMSA was performed to validate that the Δ65-LSF protein was functional and 
could bind DNA (Figure 3.5, assay performed by Laura Maciejko). In this assay, 5 nM of 
annealed oligonucleotide LSF recognition sequence was added to 0.5-30 nM of Δ65-LSF. 
At 30 nM protein, greater than 85% of DNA was reproducibly bound to the protein. Poor 
aqueous solubility of FQI-1 barred attempts to verify dihydroquinolinone inhibition of the 
protein-DNA complex. 
 
 Figure 3.5 His6 tagged Δ65-LSF binds DNA in an electromobility shift assay   
Total DNA concentration 5 nM. Assay performed by Laura Maciejko 
 
In an attempt to characterize dihydroquinolinone FQI-1 binding to recombinant 
Δ65-LSF, an in vitro fluorescence thermal stabilization assay was tried. As discussed in 
section 1.3.4, it is an accepted phenomenon that proteins often change their physical 
attributes upon binding to small molecule ligands, including stabilization to thermal 
denaturation. In the in vitro assay, thermal denaturation is monitored by fluorescence 
intensity of the dye Sypro Orange. Sypro Orange binds nonspecifically to hydrophobic 
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protein surfaces. As the protein unfolds, the exposed hydrophobic surfaces bind the dye 
resulting in an increase in fluorescence. After reaching a plateau, the fluorescence intensity 
starts to decrease due to aggregation of the denatured protein–dye complexes.57  
Unfortunately, the in vitro thermal stability assay was deemed incompatible with 
the recombinant Δ65-LSF protein. Neither FQI-1, the DNA recognition sequence used in 
the EMSA, or a combination of the two, demonstrated stabilization of Δ65-LSF. 
Reproducibly, the Tm50 of each condition was ~50°C (Figure 3.6). The initial high 
fluorescence (3000-4000) indicates dye is binding unfolded states of the protein prior to 
thermal denaturation. 
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Figure 3.6 In vitro thermal shift assay with His6 tagged Δ65-LSF  
10 μM Δ65-LSF protein was incubated with 2.5 μM DNA, 100 μM FQI-1, or a combination of both. Left 
axis: Raw fluorescence (blue) against temperature (°C): Right axis: first-derivative (red) against temperature 
(°C). Average of duplicate runs. Tm50 is the midpoint of the raw fluorescence or peak of the first derivative 
(shown as dotted gray line). All showed a Tm50 of ~50°C. 
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Circular dichroism (CD) is a useful technique for assessment of protein structure as 
well as protein-DNA binding. Circular dichroism relies on the differential absorption of 
left and right circularly polarized light by chromophores which either possess intrinsic 
chirality or are placed in chiral environments. In proteins, the relevant chromophores 
include the peptide bond (absorption below 240 nm), aromatic amino acid side chains 
(absorption in the range 260 to 320 nm) and disulfide bonds (weak broad absorption bands 
centered around 260 nm). The far UV region (190-240 nm) can be analyzed to give the 
content of regular secondary structural features such as α-helix and β-sheet whereas the 
near UV region (260-320 nm) gives information about the tertiary structure of the 
protein.97,98 When Δ65-LSF was analyzed by CD, the far-UV spectra showed a distinct 
secondary structure signature, however the near-UV spectra was near zero (Figure 3.7). 
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Figure 3.7 Circular dichroism spectra of His6 tagged Δ65-LSF   
Left: Far UV spectra shows distinct secondary structure. Right: Near UV spectra shows near zero signal. 
Insert shows zoomed in near UV spectra 
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The lack of signal in the near-UV spectrum indicated that the purified Δ65-LSF 
protein lacked a stable tertiary structure while showing secondary structural elements. The 
reproducible positive EMSA result suggested the recombinant protein was functional 
despite the apparent lack of folding. It was postulated the recombinant protein may adopt 
a “disorder-to-order” transition, analogous to p53 as discussed in section 3.2.2. To test this 
hypothesis, the Δ65-LSF  protein was titrated into the recognition sequence used in the 
EMSA and monitored in the near-UV for an “induced” CD signal (ICD) indicative of 
binding99. DNA has a strong signal in the near-UV. The signal for the DNA alone was 
subtracted from all samples containing protein. As seen in Figure 3.8, Δ65-LSF induced a 
3D structure in a dose-dependent manner upon titration with DNA. This confirmed a 
“disorder-to-order” transition. It is believed the recombinant protein is flexible in solution, 
and adopts a stable, functional, 3D fold when interacting with a binding partner. The 
dihydroquinolinones could not be tested in this method due to solubility limitations. The 
compounds can be diluted from a DMSO stock into aqueous solutions, however DMSO 
absorbs light at 250 nm and was therefore incompatible with the assay.  The disordered 
state of Δ65-LSF is believed to be akin to a molten globule; a compact, partially folded 
conformation that has substantial secondary structure, and little detectable tertiary 
structure. Molten globules are known to have a propensity to aggregate100, which offers an 
explanation for the DLS results seen with both high concentrations of Δ65-LSF , as well 
as the inability to purify full length LSF from the inclusion bodies.  
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Figure 3.8 His6 tagged Δ65-LSF adopts an induced tertiary structure upon binding DNA 
CD spectra of 30 μM Δ65-LSF with no DNA added is shown in orange. 5 μM DNA was used in all 
experiments. Signal for DNA alone was subtracted from Δ65-LSF+DNA samples. Δ65-LSF was incubated 
with DNA for 45 minutes at 37°C prior to taking spectra.     
 
 
3.3.3 Predicted disorder in full length LSF protein sequence  
 Computation analysis of the sequence composition of full length LSF protein was 
performed to predict native disorder and identify potential regions involved in induced 
folding. The metaserver MetaDisorder was used for a global analysis. MetaDisorder 
predicts disorder in proteins using existing bioinformatics tools and machine learning101. 
In this system, primary sequence is queried against 13 primary disorder prediction 
algorithms, weights their output according to method accuracy, and a final calculated 
“consensus” prediction of disorder is made101. Primary predictors fall into two classes: 
those that have been trained on data sets of disordered proteins, and those that have not. 
Each primary predictor has its own strengths and weaknesses, as well as inherent biases. 
The meta-approach allows the consolidation of different algorithms to obtain more robust 
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and accurate predictions than the use of primary predictors.91,101 
Figure 3.9 shows the predicted disorder disposition of the residues.  The DBD 
(shaded in pink) is predicted to be largely structured. As discussed in section 3.2, LSF’s 
DBD is predicted to adopt a similar fold as p53, despite sharing only ~13% sequence 
homology. The DBD of p53 is also predicted by disorder algorithms to be structured. The 
SAM domain (highlighted in orange) is also predicted to be largely structured. The 
tetramerization domain of p53 was similarly predicted to be structured, and flanked by 
unstructured regions. The UB domain (highlighted in yellow), abuts the SAM domain, and 
is predicted to be unstructured immediately following the folded SAM domain, and then 
predicted to be structured. Many post-translational modifications are found at sites of 
intrinsic disorder88. The linker region between the DBD and the C-terminal oligomerization 
domains is predicted to be largely unstructured. This region has previously been shown to 
contain phosphorylation sites at serine 291 and serine 309102,103. Activity of LSF is tightly 
controlled during G1 by phosphorylation at these two sites by both ERK and Cyclin 
C/Cdk2102,103. Phosphorylation inhibits the transcriptional activity of LSF. Both sites are 
dephosphorylated as cells progress into late G1, followed by activation of TS at the G1/S 
transition.  
The disorder prediction is consistent with the CD experiments, in which the three 
domains are predicted to adopt stable secondary structures separated by flexible 
intrinsically disordered linker regions that prevent a stable 3D fold. Analogous to p53, these 
data suggest that LSF undergoes a disorder-to-order transition when binding an interaction 
partner, such as its cognate DNA sequence. 
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Figure 3.9 MetaDisorder M2 prediction of disorder disposition of LSF protein sequence 
Above 0.5 = disordered; Below 0.5= ordered. Pink shading represents predicted DNA binding domain; 
orange shading is predicted sterile alpha motif (SAM domain) and yellow shading is predicted ubiquitin like 
fold (UB). 
 
 
3.3.4 Crystallization techniques for transcription factors 
 The purification of the LSF constructs was begun with the goal of crystallizing LSF 
(or individual LSF constructs) in order to rationally design future dihydroquinolinone 
analogs. His6 tagged Δ65-LSF emerged as the leading construct for crystallization trials. 
Δ65-LSF was routinely purified in high yields with >90% purity. When diluted below 2.5 
mg/mL a single monomodal solution with low %PD was evident by DLS. The His6 tagged 
DBD construct was also used in crystallization trials despite the higher %PD measured via 
DLS (>30%). The hanging-drop vapor diffusion method was chosen for crystallization 
trials. A sparse matrix method of buffer conditions selected from known crystallization 
conditions for proteins was used104,105. All crystallization trials were carried out at 4°C. 
Neither of the purified protein constructs yielded crystals. The majority of the drops 
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produced brown precipitated protein. Structural information about TF domains such as 
DBDs and regions of PPI are relatively abundant in the Protein Data Bank (PDB). Three 
dimensional structures of whole, non-complexed eukaryotic TFs are however completely 
absent.106 It is believed the inherent flexibility of the His6 tagged Δ65-LSF prevented 
production of protein crystals. The His6 tagged DBD construct was likely not readily 
crystallized due to the multimodal nature of the purified protein. 
 Attempts to crystallize a His6 tagged Δ65-LSF:DNA complex were also 
unsuccessful. A protein-to-DNA ratio of 1.5 and 1.2, with 1 mg/mL Δ65-LSF was tried. A 
commercially acquired PAGE gel-purified 25 base pair LSF recognition sequence was used 
for crystallization trials. A sparse-matrix method of trial conditions selected from known 
crystallization conditions for protein-nucleic acid complexes was employed105. None of the 
conditions provided crystals. It has been observed that DNA length is the key factor 
dominating whether a protein-DNA complex crystallizes. It is recommended to screen 
multiple lengths of DNA when attempting future co-crystallizations.107 In my trials, I chose 
a sequence that was similar to that used in the EMSA because the Δ65-LSF construct 
successfully bound this sequence. In future endeavors to crystallize the Δ65-LSF:DNA 
complex, it would be prudent to screen multiple lengths of DNA sequences. 
 It is likely that a combinatorial approach will be needed to solve the 3D structure 
of full length LSF. For example, the structure of p53 was resolved by a combination of 
several techniques. The p53 protein is a tetramer composed of a structured DBD and 
tetramerization domain separated by a large disordered transactivation domain and flanked 
by additional IDRs. The structured domains were solved by x-ray crystallography using a 
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covalent crosslinking method108,109. Covalent bond formation between protein and DNA 
provides a means of trapping the complex in a distinct structural state that is more readily 
crystallized110. The trapping method used for p53 DBD was disulfide trapping. A cysteine 
residue was introduced by site-directed mutagenesis into the DNA-binding surface of the 
recombinant purified p53 DBD. An alkanethiol tether was incorporated at a known nearby 
site in the protein-binding surface of the DNA through synthetic chemistry. When the 
protein binds the DNA, the cysteine and linker come close enough to form a disulfide bond, 
trapping the protein-DNA complex in the form of a cross-linked product110. This method 
allowed x-ray structure determination of a tetrameric p53 DBD bound to DNA.108,109 
Application of this technology requires some knowledge about contact points between the 
protein and DNA. The Hansen lab has previously tested single amino acid mutations in 
LSF analogous to amino acids in p53 known to be essential for DNA binding. Mutation 
activity was evaluated in EMSA and luciferase reporter assays (Steven Kim and Barbara 
Ludeke, unpublished). These data would be an excellent starting point for potential sites of 
crosslinking.   
 The structural ensemble of the p53 tertiary structure and transactivation domain 
was determined from nuclear magnetic resonance (NMR) spectroscopy and small-angle X-
ray scattering (SAXS) measurements111,112. Structure determination by NMR relies on 
recombinant expression of a protein with a uniform enrichment of 13C and 15N stable 
isotopes. Nuclear magnetic resonances from protons and isotopically labelled carbons and 
nitrogens are first measured. Internuclear distances are then inferred from perturbing the 
resonance of different atoms and observing which resonances respond.113 SAXS is directly 
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applicable to the study of flexible systems such as IDPs and multi-domain proteins with 
IDRs. SAXS is used to compute the most likely arrangement of folded domains in the full-
length protein.114 Structures of individual p53 domains, containing stable DBD mutations, 
were solved using NMR and SAXS. Results confirmed the N-terminal region within the 
full-length protein is flexible.111,112 Either of these approaches would be a viable option for 
LSF structure determination if the individual constructs could be purified. While the DBD-
LSF construct was readily purified under native conditions, the other domains were not 
accessible under the employed strategies. Efficient lysis conditions for the SAMUB-LSF 
construct need to be determined for native purification. Alternate lysis conditions could 
involve manual homogenization. The SAM-LSF and UB-LSF constructs were only 
successfully purified under denaturing conditions. The constructs were eluted as pure 
proteins from the column but were unstable and could not be refolded. It may be possible 
to try to fold them on the column prior to elution, or to test additional refolding 
environments. 
The Schaus and Hansen labs are currently investigating the LSF PPI network, 
including PPI that are positively inhibited by dihydroquinolinones. It is possible that a 
partner protein will emerge that has previously been crystallized. This would facilitate 
conditions needed for a co-crystallization experiment with either full length LSF, the Δ65-
LSF construct, or a LSF domain.  
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3.4 MATERIALS AND METHODS 
3.4.1 Cloning of LSF constructs 
The LSF constructs were cloned into a pET15b-TEV parent expression plasmid 
(provided by Dr. Karen Allen, Boston University). The plasmid contains a pET15b 
backbone encoding an N-terminal hexahistidine (His6) tag followed by a tobacco etch virus 
(TEV) protease cleavage site (ENLYFQG). Construct open reading frames were amplified 
from human LSF cDNA (provided by Gene Chin, Hansen Lab) using Pfu polymerase for 
gene products of >200 base pairs, or Taq polymerase for gene products of <200 base pairs. 
The restriction sites NdeI and BamHI were added to the 5’ and 3’ ends of the amplified 
DNA respectively. Agarose gel purified digested gene products were ligated directionally 
into the pET15b-TEV plasmid between the NdeI and BamHI sites. The ligation reaction 
was directly transformed into high efficiency NEB10β competent Escherichia coli (E. coli) 
cells (New England Biolabs). All constructs were confirmed by DNA sequencing 
(Eurofin). Purified construct plasmids were transformed into chemically competent E. coli 
strain BL21 (DE3) cells (provided by Dr. Pearlstein, Boston University) and grown on 
antibiotic selection plates. 
3.4.2 Expression of LSF constructs 
 For each construct, a single colony from a freshly streaked plate was incubated 
overnight in 20 mL LB/ampicillin growth media at 37°C, with shaking at 250 rpm. The 
following day, the 20 mL culture was added to 2 L culture volume and grown at 37°C, 
shaking at 250 rpm until the OD600 was 0.6-0.8 (approximately 2 hours). At this time, 
112 
 
 
 
constructs were induced by adding fresh IPTG to a final concentration of 0.3 mM IPTG at 
16°C for 18 hours, with shaking at ~150 rpm.  
3.4.3 Purification of His6 –tagged LSF protein constructs 
The proteins were purified using the standard His-tag purification protocol 
suggested by the manufacturer (Sigma). Following protein induction, bacterial suspensions 
were spun down at 6,000 x g for 10 minutes. Pellets were lysed with 50 mL lysis buffer 
(50 mM sodium phosphate pH 7.9, 500 mM potassium chloride, 10% glycerol, 0.03% NP-
40, 5 mM beta-mercaptoethanol, 1 mg/mL lysozyme, 1 mM pefabloc), on ice for 30 
minutes followed by sonication (6x 10 second pulses at 4°C).  Following lysis, cells were 
spun down at 30,000 x g for 30 minutes. The supernatant was passed over a 0.2 µm filter. 
All steps at this point were carried out in the cold room. Imidazole was added to the 
supernatant for a 10 mM final concentration, and the supernatant was incubated with 1 mL 
His-Select Ni-affinity resin (Sigma) for 1 hour, rotating end-over-end. After the incubation 
period, the resin was collected in a Bio-Rad poly-prep chromatography column by gravity 
flow. The resin was washed with 10 mL wash buffer 1 (50 mM sodium phosphate pH 7.9, 
500 mM potassium chloride, 10% glycerol, 0.03% NP-40, 10 mM imidazole, 5 mM beta-
mercaptoethanol), followed by wash buffer 2 (50 mM sodium phosphate pH 7.9, 500 mM 
potassium chloride, 10% glycerol, 0.03% NP-40, 20 mM imidazole, 5 mM beta-
mercaptoethanol) until the absorbance at 280 nm was ~ 0. Proteins were eluted with 50 
mM sodium phosphate pH 7.9, 500 mM potassium chloride, 10% glycerol, 0.03% NP-40, 
250 mM imidazole, 5 mM beta-mercaptoethanol. Proteins were concentrated with Ultra-4 
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centrifugal filter units (Millipore) and exchanged into a final buffer of 50 mM sodium 
phosphate pH 8.0, 500 mM potassium chloride, 20% Glycerol, 0.2 mM EDTA, 5 mM beta-
mercaptoethanol. 
 For denaturation conditions, constructs were induced as above. Cell pellets were 
resuspended in 50 mL 0.1 M Sodium phosphate pH 8, 8 M Urea, 20 mM beta-
mercaptoethanol, 1 mM pefabloc, and 1 mg/mL lysozyme, shaken 30 min on ice and 
sonicated. Imidazole was added to the lysis supernatant after spinning down at 30,000 x g 
for 30 minutes, and supernatant was incubated with 1 mL equilibrated His-select nickel 
affinity resin for one hour at 4°C. Resin was loaded onto columns as above.  Resin was 
washed twice with 10 mL 0.1 M sodium phosphate pH 6.3, 8 M urea. Proteins were eluted 
with 0.1 M Sodium Phosphate pH 4.5, 8 M Urea. Domains were dialyzed against 50 mM 
sodium phosphate, 500 mM NaCl, 10 mM beta-mercaptoethanol, at pH 5, 6, 7.4, or 8 to 
remove urea. All proteins crashed out of solution upon standing. 
3.4.4 Electromobility shift assay (EMSA) 
 EMSA was performed by Laura Maciejko. 5 nM radiolabeled double-stranded 
DNA (TGGCTGGTTATGGCTGGTCAGACTAG and its complement) was added to the 
indicated concentrations of His6 tagged Δ65-LSF for 30 min incubation at 30°C, and the 
samples electrophoresed through a native 6% polyacrylamide gel. Results were visualized 
using a Typhoon imager and quantified using ImageJ software. 
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3.4.5 Thermal stability assay 
 10 μM His6 tagged Δ65-LSF was added to 2.5 μM double-stranded DNA 
(TGGCTGGTTATGGCTGGTCAGACTAG and its complement), 100 μM FQI-1, or 
vehicle control (1% DMSO) and incubated for 30 minutes at room temperature in a PCR 
microplate. 1x Sypro orange (Sigma) was added at end of the incubation period. The 
thermal run starts at 25ºC for 30 seconds, and then takes a reading in 1ºC increments, 
holding at each temperature for 30 sec. The run goes from 25ºC to 99ºC then returns to 
25ºC.  
3.4.6 Analysis of Δ65-LSF by Circular Dichroism 
 For near and far UV studies with His6 tagged Δ65-LSF, 0.2 mg/mL of protein was 
analyzed (~3.8 μM) using a 0.2 mm pathlength rectangular cuvette on an  Applied 
Photophysics CS/2 Chirascan instrument. Protein was diluted into a 10 mM sodium 
phosphate, pH 8.0, 500 mM KCl, 10% glycerol, 0.2 mM EDTA buffer prior to reading.  
 For DNA binding studies, indicated concentrations of His6 tagged Δ65-LSF was 
added to 5 μM double-stranded DNA (TGGCTGGTTATGGCTGGTCAGACTAG and its 
complement), and incubated for 45 minutes at 30°C prior to taking CD spectra. 30 uM 
Δ65-LSF in buffer, and 5 uM DNA in buffer were scanned as controls. Signal from the 
DNA alone sample was subtracted from protein titrations. 
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3.5 CONCLUSIONS 
 Computational analysis of the full length LSF amino acid sequence suggests that 
the DNA binding domain and the tetramerization domain are structurally ordered domains 
separated by flexible linker regions. The intrinsically disordered regions in the LSF protein 
sequence are assumed to allow interaction with DNA as well as engage in protein-protein 
interactions. The inherent flexibility of the LSF protein prevented purification of full length 
LSF protein. When expressed in E. coli, the recombinant His-tagged LSF protein formed 
inseparable inclusion body aggregates. A Δ65-LSF construct, lacking the N-terminal 
transactivation domain, was purified in good yields with high purity and homogeneity. At 
high concentrations Δ65-LSF showed a propensity to aggregate into higher-order 
oligomers. Circular dichroism studies suggest that the functional Δ65-LSF protein has 
signature secondary structural elements but no native tertiary structure. Titration with DNA 
induces a three-dimensional fold as monitored in the near-UV. These results suggest that 
Δ65-LSF, and presumably full length LSF, adopt a compacted molten-globule-like form in 
which the protein contains extensive secondary structural elements but does not adopt a 
three-dimensional fold without a binding partner.  
The lack of a stable tertiary structure challenged efforts to produce an x-ray crystal 
structure of the His6 tagged Δ65-LSF protein. Crystallization attempts, with and without 
complex to a high purity LSF recognition sequence, produced aggregated and precipitated 
protein. Future endeavors to resolve the LSF protein structure, may need to involve DNA 
crosslinking, NMR or SAXS studies on the full length or individual domain constructs, or 
co-crystallization with a protein partner.  
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APPENDIX 1: ACOS Framework Calculations for Sorafenib 
Clinical Benefit Score 
Hazard Ratio (HR) for death reported: 0.69 
Clinical Benefit Score: (1-0.69) x 100 = 31 
 
Toxicity Score Sorafenib Placebo 
Grade 1-2 <10%       10  13    
Grade 1-2 >10%        7  3 
Grade 3-4 <5%       11  10  
Grade 3-4 >5%        2              0      
       32.5             24.5 
 
For every grade 1 or 2 toxicity with a frequency < 10%, record 0.5 points.  
For every grade 1 or 2 toxicity with a frequency ≥ 10%, record 1.0 points. 
For every grade 3 or 4 toxicity with a frequency < 5%, record 1.5 points. 
For every grade 3 or 4 toxicity with a frequency ≥ 5%, record 2.0 points 
 
32.5/24.5-1 = 0.33 
0.33*-20= -6.6 
 
No bonus points awarded 
 
NHB 31-6.6 =  24.4 
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APPENDIX 2: QGY-7703 MTS dose response curves  
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APPENDIX 3: NIH-3T3 MTS dose response curves 
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APPENDIX 4: LINCS Data Sensitivity Values 
 
Cell_Line Lineage AUC Cell_Line Lineage AUC
MCF7 BREAST 4.208 NCIH2122 LUNG 2.532
LN229 CENTRAL_NERVOUS_SYSTEM 3.711 NCIH596 LUNG 2.725
JHUEM2 ENDOMETRIUM 1.901 NCIH841 LUNG 2.775
HEC151 ENDOMETRIUM 2.056 NCIH1876 LUNG 2.783
SKM1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.064 HCC4006 LUNG 3.335
U937 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.120 SCLC21H LUNG 3.541
NUDUL1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.176 NCIH1836 LUNG 3.687
PL21 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.443 NCIH2081 LUNG 3.749
SUDHL5 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.562 COLO699 LUNG 3.861
GDM1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.571 HCC15 LUNG 3.976
MOLM16 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.663 NCIH1694 LUNG 4.041
KMS11 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.879 NCIH1963 LUNG 4.190
WSUDLCL2 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.922 HCC2108 LUNG 4.204
OCIAML3 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 2.160 NCIH1105 LUNG 4.279
RPMI8226 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 2.232 NCIH2073 LUNG 4.282
NOMO1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 2.472 NCIH1781 LUNG 4.450
EJM HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 2.943 NCIH2141 LUNG 4.717
AMO1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 3.011 T3M10 LUNG 4.785
THP1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 3.289 NCIH1755 LUNG 4.804
SUDHL4 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 3.825 HCC1359 LUNG 4.826
LP1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 4.143 CORL23 LUNG 4.881
OCILY10 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 4.899 SKLU1 LUNG 4.937
RCC10RGB KIDNEY 6.081 CAL12T LUNG 5.059
SNU175 LARGE_INTESTINE 2.368 CORL51 LUNG 5.130
SNUC4 LARGE_INTESTINE 2.382 HCC1833 LUNG 5.133
RKO LARGE_INTESTINE 2.420 NCIH2342 LUNG 5.145
HT115 LARGE_INTESTINE 2.604 NCIH2110 LUNG 5.211
LS180 LARGE_INTESTINE 2.924 HCC827 LUNG 5.211
KM12 LARGE_INTESTINE 2.943 NCIH2030 LUNG 5.266
SW948 LARGE_INTESTINE 2.956 NCIH3255 LUNG 5.268
LOVO LARGE_INTESTINE 3.026 NCIH441 LUNG 5.384
HCT116 LARGE_INTESTINE 3.045 NCIH460 LUNG 5.422
SNU81 LARGE_INTESTINE 3.130 NCIH2172 LUNG 5.575
SNUC5 LARGE_INTESTINE 3.366 HCC2935 LUNG 5.747
NCIH508 LARGE_INTESTINE 3.443 SQ1 LUNG 6.031
COLO320 LARGE_INTESTINE 3.741 HCC1195 LUNG 6.238
CW2 LARGE_INTESTINE 3.757 NCIH2023 LUNG 6.486
CL34 LARGE_INTESTINE 3.877 OVCAR8 OVARY 3.210
MDST8 LARGE_INTESTINE 3.937 OVCAR4 OVARY 3.274
SW620 LARGE_INTESTINE 3.938 OVK18 OVARY 3.422
SNU61 LARGE_INTESTINE 4.218 RMUGS OVARY 3.523
SNU1040 LARGE_INTESTINE 4.439 OVKATE OVARY 3.639
SW480 LARGE_INTESTINE 4.622 A2780 OVARY 3.761
HCT8 LARGE_INTESTINE 4.873 JHOM1 OVARY 3.806
RCM1 LARGE_INTESTINE 5.238 TYKNU OVARY 3.978
LS123 LARGE_INTESTINE 5.441 CAOV3 OVARY 4.041
CL40 LARGE_INTESTINE 5.485 OV90 OVARY 4.268
HT55 LARGE_INTESTINE 5.551 RMGI OVARY 4.326
HT29 LARGE_INTESTINE 6.182 COV644 OVARY 4.523
COLO678 LARGE_INTESTINE 6.194 COV434 OVARY 4.860
SNU398 LIVER 3.645 COV362 OVARY 4.942
HEPG2 LIVER 6.681 JHOC5 OVARY 5.056
A375 SKIN 2.883 SNU840 OVARY 5.157
SKMEL1 SKIN 4.392 IGROV1 OVARY 5.314
SKMEL5 SKIN 4.483 OAW42 OVARY 5.468
SKMEL28 SKIN 7.668 EFO27 OVARY 5.511
HT1080 SOFT_TISSUE 3.437 OV7 OVARY 6.021
RKN SOFT_TISSUE 4.377
AGS STOMACH 3.545
SCC9 UPPER_AERODIGESTIVE_TRACT 4.865
FQI-1
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Cell_Line Lineage AUC Cell_Line Lineage AUC
MCF7 BREAST 3.259 NCIH841 LUNG 1.343
LN229 CENTRAL_NERVOUS_SYSTEM 3.227 NCIH2122 LUNG 1.376
JHUEM2 ENDOMETRIUM 1.471 NCIH596 LUNG 1.582
HEC151 ENDOMETRIUM 1.504 SCLC21H LUNG 1.652
SKM1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 0.246 NCIH1876 LUNG 1.671
SUDHL5 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 0.358 NCIH1963 LUNG 2.176
NUDUL1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 0.384 HCC4006 LUNG 2.225
WSUDLCL2 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 0.465 NCIH1836 LUNG 2.404
PL21 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 0.588 NCIH2081 LUNG 2.452
KMS11 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 0.601 COLO699 LUNG 2.569
U937 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 0.618 HCC1359 LUNG 2.692
OCIAML3 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 0.846 NCIH1694 LUNG 2.815
MOLM16 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 0.908 NCIH1781 LUNG 2.872
GDM1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 0.966 HCC15 LUNG 2.940
NOMO1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.048 CORL23 LUNG 3.073
EJM HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.142 NCIH2073 LUNG 3.132
RPMI8226 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.285 HCC2108 LUNG 3.170
AMO1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.384 CAL12T LUNG 3.348
SUDHL4 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 1.627 CORL51 LUNG 3.689
THP1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 2.341 HCC1833 LUNG 3.719
LP1 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 2.985 NCIH2141 LUNG 4.076
OCILY10 HAEMATOPOIETIC_AND_LYMPHOID_TISSUE 3.716 NCIH1755 LUNG 4.123
RCC10RGB KIDNEY 4.203 T3M10 LUNG 4.189
SNU175 LARGE_INTESTINE 1.061 NCIH1105 LUNG 4.191
RKO LARGE_INTESTINE 1.183 NCIH2030 LUNG 4.191
SNUC4 LARGE_INTESTINE 1.302 NCIH2342 LUNG 4.410
HT115 LARGE_INTESTINE 1.377 HCC827 LUNG 4.496
SW948 LARGE_INTESTINE 1.625 NCIH460 LUNG 4.605
KM12 LARGE_INTESTINE 1.673 NCIH3255 LUNG 4.616
HCT116 LARGE_INTESTINE 1.745 NCIH2110 LUNG 4.684
LS180 LARGE_INTESTINE 1.889 SQ1 LUNG 4.703
LOVO LARGE_INTESTINE 1.892 NCIH441 LUNG 4.783
NCIH508 LARGE_INTESTINE 2.007 NCIH2172 LUNG 4.831
SNU81 LARGE_INTESTINE 2.022 SKLU1 LUNG 4.904
SNUC5 LARGE_INTESTINE 2.065 HCC2935 LUNG 5.106
CL34 LARGE_INTESTINE 2.267 HCC1195 LUNG 5.843
CW2 LARGE_INTESTINE 2.807 NCIH2023 LUNG 6.051
SNU61 LARGE_INTESTINE 2.908 OVCAR8 OVARY 1.624
MDST8 LARGE_INTESTINE 2.972 OVK18 OVARY 1.963
COLO320 LARGE_INTESTINE 3.180 OVCAR4 OVARY 2.391
SNU1040 LARGE_INTESTINE 3.467 A2780 OVARY 2.437
HCT8 LARGE_INTESTINE 3.689 OVKATE OVARY 2.539
SW620 LARGE_INTESTINE 3.798 TYKNU OVARY 3.007
CL40 LARGE_INTESTINE 3.945 JHOM1 OVARY 3.061
SW480 LARGE_INTESTINE 4.542 RMGI OVARY 3.230
LS123 LARGE_INTESTINE 4.684 RMUGS OVARY 3.332
HT55 LARGE_INTESTINE 4.785 COV644 OVARY 3.384
RCM1 LARGE_INTESTINE 4.923 OV90 OVARY 3.671
HT29 LARGE_INTESTINE 5.128 CAOV3 OVARY 3.869
COLO678 LARGE_INTESTINE 6.424 COV434 OVARY 3.963
SNU398 LIVER 2.902 COV362 OVARY 3.976
HEPG2 LIVER 5.999 OAW42 OVARY 4.316
A375 SKIN 1.912 JHOC5 OVARY 4.460
SKMEL5 SKIN 3.837 IGROV1 OVARY 4.842
SKMEL1 SKIN 4.005 SNU840 OVARY 4.850
SKMEL28 SKIN 7.432 EFO27 OVARY 4.875
HT1080 SOFT_TISSUE 2.045 OV7 OVARY 5.790
RKN SOFT_TISSUE 2.942
AGS STOMACH 1.541
SCC9 UPPER_AERODIGESTIVE_TRACT 3.186
FQI-2
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APPENDIX 5: FQI-Sorafenib co-treatment 
No synergy seen with FQI-34 
 
  
 
 
FQI-34 kept at a constant of 150 μM 
5 μM – 0.01 μM of Sorafenib added.  
Cell viability on y-axis 
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